Search Result
Results for "
IgG monoclonal antibody
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
상품명 |
Target |
연구분야 |
Chemical Structure |
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
-
- HY-P9908
-
-
-
- HY-P9906A
-
|
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
-
-
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized antibody; LDP-02; MLN-002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
-
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
-
- HY-P9909
-
-
-
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
-
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
-
- HY-164152A
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
-
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
-
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
-
-
- HY-P99979
-
-
-
- HY-P991045
-
|
mE8‑IgG2a
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (Mouse IgG2a) (mE8-IgG2a) is a mouse-derived IgG2 monoclonal antibody used in the research of Alzheimer's disease.
|
-
-
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
-
- HY-P99451
-
-
-
- HY-P990764
-
|
SGN-B6A antibody
|
Integrin
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonal antibody against ITGB6.
Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957) .
|
-
-
- HY-P99936
-
|
LJM716
|
EGFR
|
Cancer
|
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
-
-
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P99457
-
-
-
- HY-P99155
-
|
2F8; HUMAX-EGFR
|
EGFR
|
Cancer
|
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
-
-
- HY-P99108
-
-
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
-
- HY-P99305
-
-
-
- HY-P990713
-
-
-
- HY-P991197
-
|
LM-305 antibody; AZD-0305 antibody
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
-
- HY-P991422
-
-
-
- HY-P990689
-
-
-
- HY-P99643A
-
|
|
Dan family
|
Cancer
|
|
Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonal antibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
|
-
-
- HY-P990699
-
-
-
- HY-P990734
-
-
-
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P99347
-
-
-
- HY-P990767
-
-
-
- HY-P991164
-
|
AZD5335 antibody; INT-019
|
Antifolate
|
Inflammation/Immunology
|
|
Torvutatug is an anti-FOLR1 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P99034
-
-
-
- HY-P991106
-
|
LY-3076226 antibody
|
FGFR
|
Cancer
|
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P9S0056
-
-
-
- HY-P991190
-
-
-
- HY-P991175
-
-
-
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990728
-
|
SP-7219; STRO-001 antibody
|
CD74
|
Inflammation/Immunology
|
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990729
-
|
VB-119
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P990712
-
|
RZ-358; XOMA 358
|
Insulin Receptor
|
Inflammation/Immunology
|
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
-
- HY-P990737
-
|
LY-3041658
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P990773
-
|
LY-3361237
|
CD28
|
Inflammation/Immunology
|
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
-
- HY-P991191
-
-
-
- HY-P99709
-
|
LY3300054
|
PD-1/PD-L1
|
Cancer
|
|
Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody .
|
-
-
- HY-P99635
-
|
GZ-402668
|
NF-κB
|
Cancer
|
|
Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody .
|
-
-
- HY-P990755
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Pamvatamig is an anti-EGFR/MET human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990747
-
|
CM-313
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991187
-
|
AGX-101 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99155A
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
|
-
- HY-P991743
-
|
|
Ras
|
Others
|
|
Anti-KRAS Antibody is a human-derived IgG1 kappa monoclonal antibody against KRAS.
|
-
- HY-P991559
-
|
VB6-008 antibody; VB1-008
|
CD44
|
Cancer
|
|
Anti-CD44 Antibody (VB6-008 antibody) is an IgG1 monoclonal antibody against CD44, which can be used in the study of cancer .
|
-
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990143
-
|
|
LDLR
|
Others
|
|
Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) is an anti-mouse/rat/bovine VLDL-R IgG1 monoclonal antibody. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can specifically recognize VLDLR type-I and type-II expressed in CHO cells. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can be used to detect the expression of VLDLR in different cells and tissues. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) often used in western blot experiments .
|
-
- HY-P991111
-
-
- HY-P99663
-
|
AMG-994
|
TNF Receptor
|
Cancer
|
|
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .
|
-
- HY-P990727
-
-
- HY-P99324
-
|
Anti-Human EGFR Recombinant antibody; CetuxiMab-GEX, GEXMab52201
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
-
- HY-P9S0062
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) can be used in research related to ulcerative colitis .
|
-
- HY-P99495
-
|
RWJ 49004
|
HIV
|
Inflammation/Immunology
|
|
Cedelizumab (RWJ 49004) is a IgG4 monoclonal antibody targeting CD4. Cedelizumab has immunosuppressant properties .
|
-
- HY-P99200
-
-
- HY-P990147
-
|
|
VEGFR
|
Others
|
|
Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is an anti-mouse VEGFR-2 IgG2a monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is a chimeric antibody of the original DC101 antibody (HY-P990106). Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) can react with mouse VEGFR-2 .
|
-
- HY-P991166
-
|
|
Mucin
|
Others
|
|
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990030
-
-
- HY-P991169
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991188
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MGD007 is a humanized IgG1 monoclonal antibody targeting GPA33. MGD007 can be used for study of Metastatic Colorectal Cancer .
|
-
- HY-P991502
-
-
- HY-P991177
-
|
RC-108 antibody
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99447
-
|
ASN-1
|
Bacterial
|
Infection
|
|
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
|
-
- HY-P991165
-
|
KVA-12123; KVA-12.1
|
Fc Receptor (FcR)
|
Others
|
|
Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990746
-
-
- HY-P990754
-
|
M-1224
|
c-Kit
|
Inflammation/Immunology
|
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990749
-
|
AK-115
|
Trk Receptor
|
Inflammation/Immunology
|
|
Luvagrobart is an anti-NGF human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990739
-
|
BA-3071
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991117
-
|
REGN-9933
|
Factor Xa
|
Cardiovascular Disease
|
|
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990775
-
|
XTX101
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991340
-
|
|
PAI-1
|
Cardiovascular Disease
|
|
CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990768
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991116
-
-
- HY-P990705
-
|
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990725
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990771
-
|
INCA-00186
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991170
-
|
|
SARS-CoV
|
Infection
|
|
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990244
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) effectively inhibits the binding of FcRn to IgG. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is used in studies of the MHC class I heavy chain FcRn heterodimers and their interaction with IgG .
|
-
- HY-P992377
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
HY-0102 is a humanized IgG anti-NKG2A monoclonal antibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors .
|
-
- HY-P992443
-
-
- HY-P992110
-
|
DB-1311 antibody; BNT324 antibody
|
CD276/B7-H3
|
Cancer
|
|
Elfetabart (DB-1311 Antibody; BNT324 Antibody) is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992117
-
|
DCSZ-11
|
Complement System
|
Cancer
|
|
Lexucitug (DCSZ-11) is a humanized monoclonal antibody targeting CD93. The antibody isotype of Lexucitug is human IgG1κ; the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992122
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Olevaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata .
|
-
- HY-P992337
-
|
|
ROR
|
Cancer
|
|
CS5001 Antibody is an IgG1 human monoclonal antibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P992116
-
|
|
TAM Receptor
|
Cancer
|
|
Ladarutatug is a humanized monoclonal antibody targeting Tyrosine-protein kinase receptor UFO. The Ladarutatug antibody isotype is human IgG4κ; the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P992115
-
|
|
Integrin
|
Cancer
|
|
Furtisetabart is a humanized monoclonal antibody targeting CD147 with anti-tumor activity. Furtisetabart is of the human IgG4κ antibody subtype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P992203
-
|
|
CD47
|
Others
|
|
Anti-CD172a Antibody (3F9) is a humanized IgG1 monoclonal antibody targeting SIRPα/CD172a. The recommended isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P992118
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Lifonebart is a humanized monoclonal antibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992184
-
|
ASN004 antibody
|
Wnt
|
Cancer
|
|
Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) is a human IgG1 monoclonal antibody targeting TPBG. Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) can be used in cancer research. The recommended isotype control is human IgG1 kappa (HY-P99001).
|
-
- HY-D3274
-
|
|
Fluorescent Dye
|
Others
|
|
PE-Cy5 is a tandem fluorescent dye commonly used in flow cytometry, immunofluorescence, and cell biology research. It is formed by the covalent linkage of two fluorescent molecules, namely phycoerythrin and CY5. PE-Cy5 binds to human FcγRI (CD64), and this binding can be blocked by human pooled serum, anti-CD64 monoclonal antibodies targeting the ligand-binding region, or aggregated IgG. PE-Cy5 supports three-color flow cytometry analysis, and whole blood staining can partially reduce its non-specific binding (Ex/Em = 450-500 nm/665 nm) .
|
-
- HY-P99724
-
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
- HY-P992230
-
|
|
Neuropeptide Y Receptor
|
Inflammation/Immunology
|
|
Anti-Galanin Antibody is a monoclonal antibody that targets galanin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Galanin Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P992272
-
|
|
Lipocalin Family
|
Inflammation/Immunology
|
|
Anti-NGAL Antibody is a monoclonal antibody targeting NGAL. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGAL Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992296
-
|
|
PTHR
|
Inflammation/Immunology
|
|
Anti-PTHrP Antibody is a monoclonal antibody that targets PTHrP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PTHrP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992294
-
|
|
Prion Protein
|
Inflammation/Immunology
|
|
Anti-PRNP Antibody is a monoclonal antibody that targets PRNP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRNP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992285
-
-
- HY-P992256
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
Anti-LCAT Antibody is a monoclonal antibody targeting LCAT. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LCAT Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P992271
-
|
|
GDNF Receptor
|
Inflammation/Immunology
|
|
Anti-Neublastin Antibody is a monoclonal antibody targeting neublastin. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Neublastin Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P992190
-
|
|
Apelin Receptor (APJ)
|
Inflammation/Immunology
|
|
Anti-Apelin Antibody is a monoclonal antibody that targets apelin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Apelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992234
-
|
|
Glycosidase
|
Inflammation/Immunology
|
|
Anti-Heparanase Antibody is a monoclonal antibody that targets heparanase. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-heparanase antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990726
-
|
KPL-404
|
TNF Receptor
|
Inflammation/Immunology
|
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990750
-
|
IBI-110
|
LAG-3
|
Inflammation/Immunology
|
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992290
-
|
|
SHP1
|
Inflammation/Immunology
|
|
Anti-PILRA Antibody is a monoclonal antibody that targets PILRA. Anti-PILRA Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PILRA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992288
-
|
|
Serpin
|
Inflammation/Immunology
|
|
Anti-PCI Antibody is a monoclonal antibody that targets PCI. Anti-PCI Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PCI Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992467
-
|
|
ADC Antibody
Claudin
|
Cancer
|
|
SOT102 Antibody is an IgG1 monoclonal antibody targeting CLDN18.2, and the antibody of ADC SOT102. SOT102 Antibody binds selectively to CLDN18.2, and promotes internalization. SOT102 Antibody can be used for the research of cancer [2].
|
-
- HY-P992013
-
|
|
CXCR
|
Others
|
|
Anti-CXCR3 Antibody (5H7) is a mouse monoclonal antibody produced using CXCR3 as the antigen. The recommended isotype control is human IgG1 kappa (HY-P99001).
|
-
- HY-P99330
-
|
Anti-Human VEGFA Recombinant antibody; RO5520985
|
VEGFR
Tie
|
Cancer
|
|
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
|
-
- HY-P990761
-
-
- HY-P990700
-
|
RO-7247669; RG-6139
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990694
-
|
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990701
-
|
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991195
-
|
SIM1811-03
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P99893
-
|
AMG-570
|
CD28
TNF Receptor
|
Inflammation/Immunology
|
|
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases .
|
-
- HY-P991643
-
-
- HY-P99865
-
|
AK-119
|
CD73
|
Others
|
|
Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P991470
-
|
Neuradiab antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-Tenascin C Antibody (Neuradiab antibody) is a human monoclonal antibody (mAb) targeting Tenascin C. Anti-Tenascin C Antibody can be used in Glioblastoma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991041
-
|
Anti-SEZ6 antibody (SC17); ABBV-011 antibody; ABBV-706 antibody
|
ADC Antibody
|
Cancer
|
|
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99971
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990756
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990777
-
-
- HY-P990751
-
-
- HY-P991341
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
FF-21101 is a human IgG1 monoclonal antibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992123
-
|
AZD-5148
|
Bacterial
|
Infection
|
|
Ombetoxabart is a humanized IgG1-κ monoclonal antibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .
|
-
- HY-P990072
-
|
LZM-009
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
-
- HY-P990711
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P99363
-
|
Anti-ICOS/CD278 Reference antibody (feladilimab); GSK3359609
|
Transmembrane Glycoprotein
|
Cancer
|
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonal antibody. Feladilimab can be used for the research of cancer .
|
-
- HY-P991072
-
|
MAPP-66
|
HIV
HSV
|
Infection
|
|
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990995A
-
|
7G6 antibody; 7G6-IgG2a
|
Tau Protein
|
Neurological Disease
|
|
Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonal antibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease .
|
-
- HY-P9904
-
|
MPDL3280A; RG-7446; RO-5541267
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
-
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
|
-
- HY-P992148
-
|
ZL-1310 antibody
|
Notch
|
Cancer
|
|
Zocilurtatug is a human monoclonal antibody against DLL3. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992139
-
|
|
VEGFR
|
Others
|
|
Valancitug is a human monoclonal antibody targeting VEGFA. Its corresponding isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
- HY-P992194
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-BCAM Antibody is a monoclonal antibody that targets BCAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-BCAM Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992227
-
|
|
Lipase
|
Inflammation/Immunology
|
|
Anti-Endothelial Lipase Antibody is a monoclonal antibody targeting endothelial lipase. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Endothelial Lipase Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992228
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-Fibronectin III Antibody is a monoclonal antibody targeting Fibronectin III. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Fibronectin III Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P992293
-
|
|
RAR/RXR
|
Inflammation/Immunology
|
|
Anti-PRAME Antibody is a monoclonal antibody that targets the melanoma antigen preferentially/PRAME. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRAME Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992308
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-TrkC Antibody is a monoclonal antibody targeting TrkC/NTRK3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TrkC Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P992192
-
|
|
GDNF Receptor
|
Inflammation/Immunology
|
|
Anti-Artemin Antibody is a monoclonal antibody that targets artemin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-artemin antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P991391
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
|
-
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
|
|
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .
|
-
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
-
- HY-P991608
-
|
7F11C7
|
Mucin
|
Cancer
|
|
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
|
-
- HY-P992103
-
|
BNT326/YL202 antibody
|
ADC Payload
|
Cancer
|
|
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against HER3. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .
|
-
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
-
- HY-P992196
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-Canine CD28 Antibody (1C6) is a mouse-derived monoclonal antibody that targets canine CD28, which isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990027
-
|
IMGC-936 antibody; MGA021
|
ADC Antibody
MMP
|
Cancer
|
|
Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
|
-
- HY-P990865
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-CD28 Antibody (9.3) is an anti-human CD28 IgG2a monoclonal antibody. Anti-CD28 Antibody (9.3) can activate T cells. Anti-CD28 Antibody (9.3) can be used for research on immunology. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
- HY-P99037
-
|
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
-
- HY-P992096
-
|
R-1549; HMFG1; Theragyn
|
Mucin
|
Cancer
|
|
Pemtumomab Antibody (R-1549) is an anti-MUC1 monoclonal antibody. Pemtumomab Antibody is applicable to research related to breast cancer and other cancers. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P3149B
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P99054
-
|
SAR-408377; PF-08046050 antibody; SAR445953 antibody
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .
|
-
- HY-P991645
-
|
MDX-1203 antibody; BMS-936561 antibody
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
MDX-1115 is a humanized IgG1 monoclonal antibody targeting CD70. MDX-1115 can be used for synthesis of ADC BMS-936561 .
|
-
- HY-P99743
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Mitumomab is an anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-cell lung carcinoma .
|
-
- HY-P3149
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P99022
-
|
R-04909832; RG-1450
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
- HY-P3203
-
-
- HY-P990752
-
|
REGN-5678
|
CD28
|
Inflammation/Immunology
|
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992131
-
|
|
Mucin
|
Cancer
|
|
Sacomitatug is a humanized IgG1-κ monoclonal antibody targeting mucin 1 (MUC1). Sacomitatug exerts anti-tumor effects by blocking MUC1-mediated tumor proliferation signals and activating immune effectors .
|
-
- HY-P991333
-
-
- HY-P991183
-
|
|
CD28
CD38
CD3
|
Cancer
|
|
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
|
-
- HY-P991963
-
|
|
ERK
|
Others
|
|
Anti-Big-ET-1 Antibody is a humanized monoclonal antibody targeting Big-ET-1. Recommended Isotype Control: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992231
-
|
|
TAM Receptor
|
Inflammation/Immunology
|
|
Anti-GAS6 Antibody (KM5321) is a humanized anti-GAS6 monoclonal antibody. Its isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99326
-
|
Anti-Human CD20 Recombinant antibody; V10XA53
|
CD20
|
Cancer
|
|
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
|
-
- HY-P99332
-
|
Anti-Human CD3E Recombinant antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
- HY-P992277
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-NKp46 Antibody is a monoclonal antibody targeting NKp46. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NKp46 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P992250
-
|
|
Kallikrein
|
Inflammation/Immunology
|
|
Anti-KLK7 Antibody is a monoclonal antibody targeting KLK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-KLK7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992217
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CDH19 Antibody is a monoclonal antibody that targets CDH19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CDH19 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992185
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-ADAM17 Antibody is a monoclonal antibody targeting ADAM17. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADAM17 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992297
-
|
|
E1/E2/E3 Enzyme
|
Inflammation/Immunology
|
|
Anti-RNF43 Antibody is a monoclonal antibody targeting RNF43. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RNF43 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992279
-
|
|
Notch
|
Inflammation/Immunology
|
|
Anti-Notch4 Antibody is a monoclonal antibody targeting Notch4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch4 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P992186
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-ADMAST4 Antibody is a monoclonal antibody targeting ADMAST4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADMAST4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992300
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-RSPO2 Antibody is a monoclonal antibody that targets RSPO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RSPO2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992216
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD99 Antibody is a monoclonal antibody that targets CD99. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD99 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992187
-
|
|
PDI
|
Inflammation/Immunology
|
|
Anti-AGR2 Antibody is a monoclonal antibody that targets AGR2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-AGR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992307
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-TIMP-1 Antibody is a monoclonal antibody that targets TIMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TIMP-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992214
-
|
|
SHP1
|
Inflammation/Immunology
|
|
Anti-CD84 Antibody is a monoclonal antibody that targets CD84. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD84 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992251
-
-
- HY-P992197
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCL21 Antibody is a monoclonal antibody targeting CCL21. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL21 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992189
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-APCDD1 Antibody is a monoclonal antibody that targets APCDD1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-APCDD1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992255
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-LAIR1 Antibody is a monoclonal antibody that targets LAIR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LAIR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992305
-
|
|
STAT
|
Inflammation/Immunology
|
|
Anti-STAT3 Antibody is a monoclonal antibody that targets STAT3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-STAT3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992299
-
|
|
Slit Proteins
|
Inflammation/Immunology
|
|
Anti-Robo4 Antibody is a monoclonal antibody targeting Robo4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Robo4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992199
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCR9 Antibody is a monoclonal antibody targeting CCR9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCR9 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992309
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-TSPAN33 Antibody is a monoclonal antibody targeting TSPAN33. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TSPAN33 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992229
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-FZD5 Antibody is a monoclonal antibody targeting FZD5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-FZD5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992226
-
|
|
Orphan GPCR
|
Inflammation/Immunology
|
|
Anti-EMR2 Antibody is a monoclonal antibody targeting ADGRE2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-EMR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992191
-
|
|
Apolipoprotein
|
Inflammation/Immunology
|
|
Anti-ApoL1 Antibody is a monoclonal antibody that targets ApoL1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ApoL1 Antibody, please refer to Rabbit IgG1 kappa, Isotype Control (HY-P99980).
|
-
- HY-P992269
-
|
|
Monocarboxylate Transporter
|
Inflammation/Immunology
|
|
Anti-MSR1 Antibody is a monoclonal antibody that targets MSR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MSR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992222
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCL13 Antibody is a monoclonal antibody targeting CXCL13. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CXCL13 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992263
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-LRP5 Antibody is a monoclonal antibody that targets LRP5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992287
-
|
|
Protein Arginine Deiminase
|
Inflammation/Immunology
|
|
Anti-PAD4 Antibody is a monoclonal antibody that targets PAD4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PAD4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992278
-
|
|
Notch
|
Inflammation/Immunology
|
|
Anti-Notch2 Antibody is a monoclonal antibody targeting Notch2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
-
- HY-P99357
-
|
REGN1193; Anti-GCGR Reference antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
-
- HY-P99494
-
|
TRC105; DE-122
|
TGF-beta/Smad
|
Cancer
|
|
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
|
-
- HY-P3203A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-P99195
-
|
REGN-475; SAR-164877
|
Trk Receptor
|
Inflammation/Immunology
|
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
-
- HY-P991179
-
|
|
TNF Receptor
|
Cancer
|
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
-
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
-
- HY-P990745
-
|
HIB210; MOR044254; MOR210; TJ-210; TJ-210001; WBP2191
|
Complement System
|
Inflammation/Immunology
|
|
Izastobart is an anti-C5AR1 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P992375
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HuMax-IL15 is a human IgG1 monoclonal antibody against IL-15. HuMax-IL15 is applicable to the research of rheumatoid arthritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P990691
-
-
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990037
-
|
GEN3014
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .
|
-
- HY-P99909
-
|
PF-06863135; RN-613
|
TNF Receptor
|
Inflammation/Immunology
|
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990692
-
|
JNJ-70218902; JNJ-902
|
CD3
|
Inflammation/Immunology
|
|
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990139
-
|
|
CD20
|
Inflammation/Immunology
|
|
Anti-Mouse CD20 Antibody (AISB12) is an anti-mouse CD20 IgG2a monoclonal antibody. Anti-Mouse CD20 Antibody (AISB12) can deplete B cells. Anti-Mouse CD20 Antibody (AISB12) can be used for research on immunology .
|
-
- HY-P99328
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
-
- HY-P992295
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Protein S Antibody is a monoclonal antibody targeting Protein S. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Protein S Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992292
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Plexin A1 Antibody is a monoclonal antibody targeting Plexin A1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Plexin A1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992261
-
|
|
Lipocalin Family
|
Inflammation/Immunology
|
|
Anti-Lipocalin-2 Antibody is a monoclonal antibody targeting Lipocalin-2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Lipocalin-2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992248
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-32 Antibody is a monoclonal antibody that targets IL-32. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-32 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992240
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-19 Antibody is a monoclonal antibody that targets IL-19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-19 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P992245
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-26 Antibody is a monoclonal antibody that targets IL-26. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-26 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992218
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CHRDL-1 Antibody is a monoclonal antibody that targets CHRDL-1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CHRDL-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992243
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-24 Antibody is a monoclonal antibody that targets IL-24. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-24 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992267
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-MMP-16 Antibody is a monoclonal antibody targeting MMP-16. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MMP-16 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990803
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonal antibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
- HY-P992213
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD79 Antibody is a monoclonal antibody that targets CD79. Anti-CD79 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD79 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992274
-
|
|
Transglutaminase
|
Inflammation/Immunology
|
|
Anti-NGLY1 Antibody is a monoclonal antibody that targets NGLY1. Anti-NGLY1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGLY1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990245
-
|
|
FAP
|
Cancer
|
|
Anti-Mouse FAP Antibody (73.3) is an anti-mouse FAP IgG1 monoclonal antibody. Anti-Mouse FAP Antibody (73.3) can be used to accurately detect the expression and localization of FAP protein in mice. Anti-Mouse FAP Antibody (73.3) can be used for research on cancer .
|
-
- HY-P992265
-
|
|
Monocarboxylate Transporter
|
Inflammation/Immunology
|
|
Anti-MCT1 Antibody is a monoclonal antibody that targets MCT1. Anti-MCT1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MCT1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992204
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD180 Antibody is a monoclonal antibody that targets CD180. Anti-CD180 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD180 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992268
-
|
|
MEK
|
Inflammation/Immunology
|
|
Anti-MP1 Antibody is a monoclonal antibody that targets MP1. Anti-MP1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MP1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991305
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
|
-
- HY-P991314
-
|
|
MDM-2/p53
|
Cancer
|
|
NMC-001 is a human IgG1 monoclonal antibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99322
-
|
LFG316; Anti-Human C5 Recombinant antibody
|
Complement System
|
Inflammation/Immunology
|
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
-
- HY-P9905
-
|
C225; IMC-C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
- HY-P3149A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P991681
-
|
ASP-2138
|
Claudin
CD3
|
Cancer
|
|
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
|
-
- HY-P991546
-
|
|
CD20
|
Cancer
|
|
MEDI-552 is a human IgG monoclonal antibody targeting CD20/membrane-spanning 4-domains subfamily A member 1 (MS4A1) .
|
-
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
-
- HY-P99831
-
|
GB-221
|
EGFR
|
Others
Cancer
|
|
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
|
-
- HY-P991903
-
|
|
CD20
|
Cancer
|
|
PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
|
-
- HY-P99465
-
-
- HY-P992252
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-Kremen2 Antibody is a monoclonal antibody that targets Kremen2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Kremen2 Antibody, please refer to Human IgG1 (N297A) kappa, Isotype Control (HY-P99994).
|
-
- HY-P992207
-
|
|
SHP1
|
Inflammation/Immunology
|
|
Anti-CD300A Antibody is a monoclonal antibody targeting CD300A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300A Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P992210
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD326 Antibody (17-1A) is a human monoclonal antibody targeting CD326. Anti-CD326 Antibody (17-1A) can be used in cancer research. The recommended isotype control is Mouse IgG1 kappa (HY-P99977).
|
-
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992125
-
|
HFB-200603
|
CD28
|
Cancer
|
|
Radanstobart (HFB-200603) is a humanized monoclonal antibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991460
-
|
|
TNF Receptor
|
Cancer
|
|
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992412
-
|
|
Claudin
|
Cancer
|
|
MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P992198
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCL28 Antibody is a monoclonal antibody targeting CCL28. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL28 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99307
-
|
AMG-203; Anti-Human CSF2 Recombinant antibody
|
c-Fms
|
Inflammation/Immunology
|
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
-
- HY-P991670
-
|
AVTX-009
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abdakibart is a humanized IgG4 monoclonal antibody inhibitor targeting IL-1β. Abdakibart can be used for inflammatory disease like type 2 diabetes research .
|
-
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
-
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
-
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
-
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
-
- HY-P99262
-
|
BAX69; Anti-Human MIF Recombinant antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .
|
-
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
-
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
-
- HY-P9925
-
|
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
-
- HY-P990036
-
|
PF-06823859
|
IFNAR
|
Inflammation/Immunology
|
|
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
|
-
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
-
- HY-P992225
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-DR3 Antibody is a monoclonal antibody that targets DR3. Anti-DR3 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DR3 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99271
-
|
Anti-Human F3 Recombinant antibody
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
|
-
- HY-P992224
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-DKK2 Antibody is a monoclonal antibody that targets DKK2. Anti-DKK2 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DKK2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99009
-
|
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
-
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
- HY-P99368
-
|
MCS110
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
-
- HY-P991484
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990007
-
|
PRA023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
|
-
- HY-P991450
-
|
ADI-15742; MBP-134 AF
|
Filovirus
|
Infection
|
|
ADI-15878 is a human IgG monoclonal antibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991489
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ENx-108A is a human IgG4 monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991483
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990086
-
|
RG-6292; RO-7296682
|
Interleukin Related
|
Cancer
|
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity .
|
-
- HY-P991942
-
|
BAY3375968; TPP-23411
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
|
-
- HY-P992249
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-34 Antibody is a monoclonal antibody that targets IL-34. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-34 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992128
-
|
|
EGFR
|
Others
|
|
Rinumafusp alfa is a human monoclonal antibody targeting ERBB3/HER3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99181
-
-
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
- HY-P99670
-
-
- HY-P99695
-
|
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
-
- HY-P99423
-
|
ADG 20
|
SARS-CoV
|
Infection
|
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
-
- HY-P99955
-
-
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
-
- HY-P991434
-
|
|
Integrin
|
Inflammation/Immunology
|
|
SAN-300 is a human IgG1 monoclonal antibody (mAb) targeting ITGA1/VLA-1. SAN-300 can be used in Rheumatoid arthritis research .
|
-
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
-
- HY-P991721
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
|
-
- HY-P99053
-
-
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99889
-
|
BRII-198
|
SARS-CoV
|
Infection
|
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
- HY-P9S0008
-
|
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
|
-
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
-
- HY-P99366A
-
|
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
-
- HY-P991300
-
|
|
LAG-3
|
Cancer
|
|
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
-
- HY-P992258
-
|
|
RXFP Receptor
|
Inflammation/Immunology
|
|
Anti-LGR7 Antibody is a monoclonal antibody targeting LGR7/RXFP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGR7 Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P992310
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-UPK-1B Antibody is a monoclonal antibody targeting UPK1B. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-UPK-1B Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992208
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD300C Antibody is a monoclonal antibody targeting CD300C. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300C Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992257
-
|
|
Galectin
|
Inflammation/Immunology
|
|
Anti-LGALS3BP Antibody is a monoclonal antibody targeting LGALS3BP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGALS3BP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992306
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-TEM8 Antibody is a monoclonal antibody targeting TEM8/ANTXR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TEM8 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991110
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonal antibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
|
-
- HY-P992276
-
-
- HY-P992302
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-SEMA3A Antibody is a monoclonal antibody targeting SEMA3A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-SEMA3A Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992273
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-NGF2 Antibody is a monoclonal antibody targeting NGF2/NT-3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGF2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P992195
-
|
|
FGFR
|
Inflammation/Immunology
|
|
Anti-Beta Klotho Antibody is a monoclonal antibody targeting *Beta Klotho*. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Beta Klotho Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P992051
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990797
-
|
|
IFNAR
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IFN gamma Antibody (R4-6A2) is an anti-mouse IFN gamma IgG1 monoclonal antibody. Anti-Mouse IFN gamma Antibody (R4-6A2) can increase the total serum IgG level. Anti-Mouse IFN gamma Antibody (R4-6A2) can be used for researches on immunology and infection conditions such as nymphs infection. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
- HY-P990818
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991374
-
|
|
Tau Protein
|
Neurological Disease
|
|
PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991442
-
|
TAK-920
|
TREM receptor
|
Neurological Disease
|
|
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99900
-
|
MSL-109
|
CMV
|
Infection
|
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
-
- HY-P991399
-
-
- HY-P99411
-
|
SHP647
|
Integrin
|
Inflammation/Immunology
|
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
|
-
- HY-P99362
-
|
Anti-MUC5AC Reference antibody (ensituximab); NEO-102
|
Mucin
|
Cancer
|
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
|
-
- HY-P992402
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MAI1738 is a human monoclonal antibody targeting PODXL. MAI1738 can be used for cancer-related research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99462
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
-
- HY-P99040
-
|
JNJ-61610588; CI-8993; VSTB112
|
VISTA
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
|
-
- HY-P992486
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
XKH001 is a recombinant humanized IgG1 monoclonal antibody targeting IL-25. XKH001 has low immunogenicity. XKH001 can be used for the research of type 2 inflammatory diseases .
|
-
- HY-P992235
-
-
- HY-P992221
-
|
|
Gap Junction Protein
|
Inflammation/Immunology
|
|
Anti-CLDN9 Antibody is a monoclonal antibody targeting CLDN9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CLDN9 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P992188
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Anti-ALK7 Antibody is a monoclonal antibody that targets ALK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ALK7 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P992289
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Anti-PD-L2 Antibody is a monoclonal antibody targeting PD-L2/CD273. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PD-L2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P992246
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-27RA Antibody is a monoclonal antibody that targets IL-27RA. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-27RA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992264
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-LRP6 Antibody is a monoclonal antibody that targets LRP6. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP6 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P992236
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-17F Antibody is a monoclonal antibody that targets IL-17F. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17F Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992253
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-L1-CAM Antibody is a monoclonal antibody that targets L1-CAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-L1-CAM Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991723
-
|
CX-2051 antibody
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .
|
-
- HY-P992242
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-23R Antibody is a monoclonal antibody that targets IL-23R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-23R Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992298
-
|
|
Slit Proteins
|
Inflammation/Immunology
|
|
Anti-ROBO2 Antibody is a monoclonal antibody targeting ROBO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ROBO2 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P992193
-
|
|
APC
|
Inflammation/Immunology
|
|
Anti-B7-H7 Antibody is a monoclonal antibody targeting HHLA2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-B7-H7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992237
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-17RB Antibody is a monoclonal antibody targeting IL-17RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17RB Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992205
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD226 Antibody is a monoclonal antibody targeting CD226. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD226 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P990150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse TSLP Antibody (28F12) is an anti-mouse TSLP IgG2a monoclonal antibody. Anti-Mouse TSLP Antibody (28F12) weakens skin inflammation and allergic reactions by reducing Treg cells and lymph node cells. Anti-Mouse TSLP Antibody (28F12) can be used for research on allergic conditions .
|
-
- HY-P990302
-
|
|
nAChR
|
Neurological Disease
|
|
Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonal antibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models .
|
-
- HY-P991404
-
|
|
TNF Receptor
|
Cancer
|
|
AMG-228 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. AMG-228 can be used in advanced solid tumors research .
|
-
- HY-P99591
-
|
AS1402; huHMFG-1; Epitumomab
|
Mucin
|
Cancer
|
|
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
|
-
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
-
- HY-P991433
-
|
|
TNF Receptor
|
Cancer
|
|
BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
|
-
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
-
- HY-P990766
-
|
AZD3152
|
SARS-CoV
|
Infection
|
|
Sipavibart (AZD3152) is a human IgG1 λ2 monoclonal antibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P99729
-
|
GSK 3772847; CNTO-7160
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma .
|
-
- HY-P991495
-
|
|
RSV
|
Infection
|
|
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991301
-
|
|
LAG-3
|
Cancer
|
|
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P992132
-
|
STAR-0310
|
TNF Receptor
|
Inflammation/Immunology
|
|
Solaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4/OX40L. Solaprubart regulates immune homeostasis by blocking the OX40L-OX40 signaling pathway and can be used for the research of autoimmune diseases such as atopic dermatitis .
|
-
- HY-P990591
-
|
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-1070806 (Aletekitug) is a humanized IgG1/κ monoclonal antibody targeting IL-18. GSK-1070806 neutralizes IL-18 activity.GSK-1070806 can be used for the research of inflammation. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991279
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonal antibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
|
-
- HY-P991840
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD68 Antibody (KP1) is a anti-CD68 monoclonal antibody (mAb). CD68 is present in various cell types, including monocytes/macrophages and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991523
-
|
|
Apoptosis
|
Cancer
|
|
BI-836826 is a IgG1 chimerized and Fc-engineered anti-CD37 monoclonal antibody. BI 836826 displays both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic activities. BI-836826 can be used for the study of chronic lymphocytic leukemia .
|
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-P99271A
-
|
Anti-Human F3 Recombinant antibody (powder)
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
|
-
- HY-P99677
-
|
ZTS-00075623
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonal antibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis .
|
-
- HY-P99514
-
|
AGEN1884
|
CTLA-4
|
Cancer
|
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
-
- HY-P99485
-
|
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
-
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
-
- HY-P991711
-
|
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Povovetug is a humanized IgG1κ chimeric monoclonal antibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
|
-
- HY-P991334
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
INCAGN1949 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. INCAGN1949 selectively deplete intratumoral regulatory T cells .
|
-
- HY-P992219
-
|
|
Claudin
|
Inflammation/Immunology
|
|
Anti-Claudin 1 Antibody is a monoclonal antibody targeting CLDN1/CLD1/SEMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Claudin 1 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992239
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-18Rα Antibody is a monoclonal antibody targeting IL-18Ra. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18Rα Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991431
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD133/PROM1 Antibody (CMab-43) is a human IgG2a monoclonal antibody (mAb) targeting PROM1/CD133. Anti-CD133/PROM1 Antibody (CMab-43) can be used in colon cancer research .
|
-
- HY-P992260
-
|
|
LILRB
|
Inflammation/Immunology
|
|
Anti-LILRB3 Antibody is a monoclonal antibody targeting LILRB3/ILT5/CD85a. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992259
-
|
|
LILRB
|
Inflammation/Immunology
|
|
Anti-LILRB1 Antibody is a monoclonal antibody targeting LILRB1/CD85j/ILT2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992286
-
|
|
P2X Receptor
|
Inflammation/Immunology
|
|
Anti-P2XR4 Antibody is a monoclonal antibody targeting P2XR4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-P2XR4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992303
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Siglec-10/CD24 Antibody is a monoclonal antibody targeting Siglec-10. It can be used in ELISA, FACS, and functional assays. Isotype controls for Anti-Siglec-10/CD24 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990868
-
|
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonal antibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982) .
|
-
- HY-P990870
-
|
|
CD19
IFNAR
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991869
-
|
AQmabAM; rAb-53
|
Aquaporin
|
Neurological Disease
|
|
Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
|
-
- HY-P990110
-
|
Mab158
|
Amyloid-β
|
Neurological Disease
|
|
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
|
-
- HY-P99289
-
|
antibody hLL 2; AMG-412
|
CD22
|
Inflammation/Immunology
Cancer
|
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
|
-
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human anti-IL31 IgG1-κ monoclonal antibody. BMS-981164 effectively inhibits the IL-31 signaling pathway. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 is applicable to research related to atopic dermatitis .
|
-
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991482
-
|
|
Influenza Virus
|
Infection
|
|
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992400
-
|
|
Tau Protein
|
Neurological Disease
|
|
Lu AF87908 is an IgG1 monoclonal antibody targeting the p-Ser396/404 epitope of tau protein, which mainly binds to the pSer396 region. Lu AF87908 can be used in the research of Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
-
- HY-P99353
-
|
Anti-ACVRL1 / ALK-1 Reference antibody (ascrinvacumab); PF-03446962; GT-90001C
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
-
- HY-P991690
-
|
|
RSV
|
Infection
|
|
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
|
-
- HY-P991471
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
GB-0895 is a human monoclonal antibody (mAb) targeting TSLP. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99185
-
|
AAB-001
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
-
- HY-P991688
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
|
-
- HY-P99183
-
|
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
|
-
- HY-P991717
-
|
AZD-8630
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
|
-
- HY-P992373
-
|
|
Mucin
|
Cancer
|
|
huCC49 is a human monoclonal antibody targeting TAG-72. huCC49 can be used in cancer-related research. The recommended isotype control is human IgG1 kappa, with the isotype control (HY-P99001) .
|
-
- HY-P992182
-
|
|
Interleukin Related
IFNAR
CD28
|
Inflammation/Immunology
|
|
ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].
|
-
- HY-P990241
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR (D265A) Antibody (DTA-1) is an anti-mouse GITR IgG1 monoclonal antibody. Anti-Mouse GITR (D265A) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (D265A) Antibody (DTA-1) contains the D265A mutation region. Anti-Mouse GITR (D265A) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (D265A) Antibody (DTA-1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990240
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is an anti-mouse GITR IgG2a monoclonal antibody. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) contains the LALA-PG mutation region. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P99128
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8 + T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology .
|
-
- HY-P990159
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCRβ Antibody (HB218) is an anti-mouse TCRβ IgG2b monoclonal antibody. Anti-Mouse TCRβ Antibody (HB218) can deplete TCRβ + T cells. Anti-Mouse TCRβ Antibody (HB218) can be used for research on inflammation conditions and cancer such as spontaneous dermatitis and squamous cell carcinoma (SCC) .
|
-
- HY-P992238
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-18RAP Antibody is a monoclonal antibody targeting IL-18RAP/IL-18RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18RAP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992280
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-NRP2 Antibody is a monoclonal antibody targeting NRP2/VEGF165R2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NRP2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P992133
-
|
SYS6002 antibody; CRB-701 antibody
|
ADC Antibody
Nectin-4
|
Cancer
|
|
Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991454
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-LGR5/GPR49 Antibody (18G7H6A3) is a human monoclonal antibody (mAb) targeting LGR5/GPR49. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991453
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonal antibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
-
- HY-P99730
-
|
TAK-079
|
CD38
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
|
-
- HY-P991892
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 is a humanized anti-CD4 monoclonal IgG1 antibody. IT1208 depletes CD4 + T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research .
|
-
- HY-P99945
-
-
- HY-P99041
-
|
ABX-EGF
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
-
- HY-P991554
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
|
-
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
-
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
-
- HY-P9801
-
|
SARS-CoV-2 (2019-nCoV) Spike RBD antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
- HY-P990838
-
|
|
Interleukin Related
IFNAR
|
Inflammation/Immunology
|
|
Anti-IL-12 p70 Antibody (20C2) is an anti-human IL-12 p70 IgG1 monoclonal antibody. Anti-IL-12 p70 Antibody (20C2) can inhibit the production of IFN-γ. Anti-IL-12 p70 Antibody (20C2) can be used for research on inflammation conditions. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991292
-
|
|
ADC Antibody
|
Cancer
|
|
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991448
-
|
|
Glycoprotein VI
|
Cancer
|
|
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991112
-
|
|
Transmembrane Glycoprotein
|
Infection
|
|
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
|
-
- HY-P990146
-
|
|
Ras
|
Inflammation/Immunology
|
|
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is an anti-mouse/rat/human v-H-Ras IgG2a monoclonal antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) can be used as a control antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is often used for immunofluorescence and immunoprecipitation .
|
-
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .
|
-
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
-
- HY-P991421
-
|
|
VISTA
|
Cancer
|
|
W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
|
-
- HY-P992141
-
-
- HY-P99041B
-
|
ABX-EGF (powder)
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
|
-
- HY-P99513
-
|
CTB011
|
RABV
|
Infection
|
|
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
|
-
- HY-P991192
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
|
-
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
-
- HY-P99904
-
|
MEDI-507; TCD601
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
-
- HY-P991652
-
|
RG-7594
|
Integrin
|
Cancer
|
|
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
|
-
- HY-P991473
-
|
|
TNF Receptor
|
Cancer
|
|
hCBE-11 is a human monoclonal antibody (mAb) targeting TNFRSF3. hCBE-11 can be used in solid tumors research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9807
-
|
SARS-CR3022; SARS-CoV-2 antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
-
- HY-P991507
-
|
Demupitamab
|
EGFR
|
Cancer
|
|
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
|
-
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
- HY-P9968
-
|
h-R3
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
-
- HY-P990869
-
|
|
CD1
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P990790
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonal antibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8 + T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
-
- HY-P9990
-
-
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
-
- HY-P99701
-
|
BMS-986004
|
TNF Receptor
|
Inflammation/Immunology
|
|
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
|
-
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
|
-
- HY-P991589
-
|
NOV-1105
|
c-Met/HGFR
|
Cancer
|
|
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
|
-
- HY-P991612
-
|
Sym024
|
CD73
|
Inflammation/Immunology
Cancer
|
|
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
|
-
- HY-P99283
-
|
NN 7415; mAb 2021; Anti-TFPI Recombinant antibody
|
Factor Xa
|
Others
|
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
|
-
- HY-P990006
-
|
TEV-48574; SAR-447189; TEV-574
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
-
- HY-P991311
-
|
|
LPL Receptor
Wnt
|
Cancer
|
|
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
- HY-P992241
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-21R Antibody is a monoclonal antibody targeting IL-21R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-21R Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
- HY-P992346
-
|
|
CD47
|
Cancer
|
|
DS-1103a is a humanized IgG4 monoclonal antibody targeting SIRPa/CD172a. DS-1103a inhibits the interaction between SIRPα and CD47. DS-1103a enhances antibody-dependent cellular phagocytosis of cancer cells. DS-1103a can be used for the research of solid tumors. The recommended isotype control is: Human IgG4 (S228P) kappa, (HY-P99003) .
|
-
- HY-P991458
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9965
-
|
HuLuc 63; PDL 063; BMS 901608
|
Transmembrane Glycoprotein
|
Cancer
|
|
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
|
-
- HY-P99313
-
|
Anti-Human IGHE Recombinant antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-108730
-
|
Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
|
-
- HY-P99194
-
|
REGN1500
|
ANGPTL
|
Cardiovascular Disease
Metabolic Disease
|
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
-
- HY-P99335
-
|
Anti-Human IL17A Recombinant antibody; SHR-1314
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .
|
-
- HY-P990179
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2AB6 Antibody (16A11) is an anti-mouse NKG2AB6 IgG2b monoclonal antibody. Anti-Mouse NKG2AB6 Antibody (16A11) reduces depletion of antigen-specific CD8 T cells. Anti-Mouse NKG2AB6 Antibody (16A11) can be used for research on cancer such as lung cancer and colon cancer .
|
-
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
-
- HY-P992411
-
|
|
Amyloid-β
|
Neurological Disease
|
|
MEDI-8490 is a fully human monoclonal antibody targeting APP/Aβ. MEDI-8490 can be used in research related to neurodegenerative diseases. Recommended isotype control: Human IgG1 lambda1, Isotype Control (HY-P99992).
|
-
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
- HY-P99786
-
|
REGN3918
|
Complement System
|
Metabolic Disease
|
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
-
- HY-P99110
-
|
SHP643; DX-2930; X124-G01
|
Kallikrein
|
Inflammation/Immunology
|
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
-
- HY-P990145
-
|
|
VISTA
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF .
|
-
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
-
- HY-P990792
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 + T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
- HY-P990730
-
|
ARB202
|
CD3
Cadherin
|
Cancer
|
|
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .
|
-
- HY-P991393
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
ASP8374 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991445
-
|
|
SARS-CoV
|
Infection
|
|
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991493
-
|
|
RSV
|
Infection
|
|
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P992063
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonal antibody that binds to CD8α on mouse CD8 + T cells. When used in combination with a non-depleting anti-CD4 antibody, Anti-Mouse CD8α Antibody (YTS 105.18) does not deplete CD8 + T cells, but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used for research on graft rejection. The recommended isotype control is Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
- HY-P99114
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
-
- HY-P991516
-
|
|
Factor VIII
|
Cardiovascular Disease
|
|
TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) .
|
-
- HY-P99036
-
|
|
Tie
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches .
|
-
- HY-P9915
-
|
Anti-Human CD38, Human antibody; HuMax-CD38; JNJ-54767414
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P99351
-
|
Anti-MMP9 Reference antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-P991689
-
|
|
VEGFR
|
Cancer
|
|
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
|
-
- HY-P99041A
-
|
|
EGFR
|
Cancer
|
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
-
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
-
- HY-P99376
-
|
OMS 721; Anti-MASP2 Reference antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
-
- HY-16261A
-
|
(E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone
|
ADC Payload
Topoisomerase
|
Cancer
|
|
MC-DOXHZN ((E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone) is an albumin-binding proagent of Doxorubicin (HY-15142A) (DNA topoisomerase II inhibitor), with acid-sensitive properties. MC-DOXHZN can be used to synthesize ADC .
|
-
- HY-P991426
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
|
-
- HY-P9968A
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-171265
-
|
MRG003
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
|
-
- HY-P99263
-
|
Anti-Human selectin P Recombinant antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
- HY-P990109
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC50s of >1 μM and 0.2 nM for monomeric Aβ1-40 and fibrillar Aβ1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .
|
-
- HY-P99970
-
|
|
ADC Antibody
Sodium Phosphate Cotransporter
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992167
-
|
|
Claudin
|
Cancer
|
|
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .
|
-
- HY-P99490
-
|
hzVSF-v13
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
|
-
- HY-P99216
-
|
PF-04360365; RN 1219
|
Amyloid-β
|
Neurological Disease
|
|
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .
|
-
- HY-P99287
-
|
B-E8; Anti-IL-6 MAB B-E8
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
|
-
- HY-P99220
-
|
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
-
- HY-P9907A
-
|
Anti-Human HER2, Humanized antibody (anti-HER2)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
- HY-P99317
-
|
LY-2062430
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
|
-
- HY-P99336
-
|
BI-RR 0001; Anti-Human IL6 Recombinant antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
-
- HY-P990714
-
|
|
CD3
|
Inflammation/Immunology
|
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
-
- HY-P991496
-
|
|
RSV
|
Infection
|
|
IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-P990124
-
|
|
TNF Receptor
NF-κB
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
- HY-P9929
-
|
BLA761046; MBL-CDB1; MDX-1388
|
Bacterial
|
Infection
|
|
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
|
-
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-P992399
-
|
|
TNF Receptor
NF-κB
|
Cancer
|
|
LBL-019 is a humanized IgG1 monoclonal antibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P990800
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse IL-4 Antibody (BVD6-24G2) is an anti-mouse IL-4 IgG1 monoclonal antibody. Anti-Mouse IL-4 Antibody (BVD6-24G2) can inhibit IL-4 signaling and promote Treg differentiation. Anti-Mouse IL-4 Antibody (BVD6-24G2) can be used for research on immunology. The recommend isotype control of Anti-Mouse IL-4 Antibody (BVD6-24G2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
- HY-P991465
-
|
|
TNF Receptor
|
Cancer
|
|
Anti-CD27 Antibody (M2177) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2177) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2177) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991466
-
|
|
TNF Receptor
|
Cancer
|
|
Anti-CD27 Antibody (M2191) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2191) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2191) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990207
-
|
|
Integrin
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is an anti-mouse/human Integrin β7 IgG2a monoclonal antibody. Anti-Mouse/Human Integrin β7 Antibody (FIB504) can reduce the residence of type 2 innate lymphoid cells (ILC2s). Anti-Mouse/Human Integrin β7 Antibody (FIB504) can be used for researches on inflammation conditions and cancer such as lupus nephritis and glioma .
|
-
- HY-P990181
-
|
|
Glutathione Peroxidase
STING
|
Inflammation/Immunology
|
|
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonal antibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) .
|
-
- HY-P990051
-
|
AOC-1001 antibody; AOC-1044 antibody
|
Transferrin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Delpacibart is a humanized IgG1κ monoclonal antibody targeting the transferrin receptor TFRC. Delpacibart can be conjugated with the phosphorodiamidate morpholino oligonucleotide (PMO) Zotadirsen (HY-177972), which targets exon 44 of the dystrophin gene, to synthesize the antibody-oligonucleotide conjugate (AOC) Delpacibart zotadirsen (HY-177564). Delpacibart is suitable for use in Duchenne muscular dystrophy (DMD44) research .
|
-
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
-
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
-
- HY-P99039
-
|
MEDI9447
|
CD73
|
Cancer
|
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
-
- HY-P991593
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
|
-
- HY-W043748
-
|
N-Succinimidyl acrylate
|
Biochemical Assay Reagents
|
Others
|
|
2,5-Dioxopyrrolidin-1-yl acrylate (N-Succinimidyl acrylate) is a protein crosslinker. 2,5-Dioxopyrrolidin-1-yl acrylate can react with a monoclonal anti-horseradish peroxidase IgG antibody (anti-HRP) to modify lysine residues .
|
-
- HY-P99727
-
|
CTB012
|
RABV
|
Infection
|
|
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
|
-
- HY-P99541
-
|
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
-
- HY-P991345
-
|
AMP-514
|
PD-1/PD-L1
|
Cancer
|
|
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
|
-
- HY-P992215
-
|
|
LILRB
|
Inflammation/Immunology
|
|
Anti-CD85a/LILRB3 Antibody (7C5) is a human monoclonal antibody targeting LILRB3/ILT5/CD85a. Anti-CD85a/LILRB3 Antibody (7C5) can be used for research on inflammatory and immune diseases. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).
|
-
- HY-P992156
-
|
|
LAG-3
|
Cancer
|
|
Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonal antibody that specifically binds to human, mouse and bovine LAG-3. Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) can be used in the research of colon cancer, colorectal cancer and rectal cancer. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-132253A
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-P991196
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990015
-
|
VIR-3434
|
HBV
|
Infection
|
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990867
-
|
|
Insulin Receptor
Akt
|
Cancer
|
|
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is an anti-human CD220/Insulin Receptor IgG1 monoclonal antibody. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can block Akt overactivation caused by Trip13 deficiency. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can be used for research on cancer such as hepatocellular carcinoma (HCC). Anti-CD220/Insulin Receptor Antibody (IR 83-22) often used in western blotting. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P990855
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
- HY-P9915A
-
|
Anti-Human CD38, Human antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P991237
-
|
HMBD-001
|
EGFR
|
Cancer
|
|
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
|
-
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
- HY-P99299
-
|
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
-
- HY-141604
-
|
CDX-011; CR011-vcMMAE
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
|
-
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
-
- HY-P992008
-
|
|
TGF-β Receptor
|
Cardiovascular Disease
|
|
PF-07868489 is a recombinant monoclonal antibody targeting GDF2/BMP-9. PF-07868489 can be used for the research of pulmonary arterial hypertension (PAH). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990031
-
|
M-6223
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
-
- HY-P99143
-
|
|
Neurokinin Receptor
NF-κB
STAT
|
Inflammation/Immunology
|
|
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P990126
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
|
|
Anti-Rat CD8α Antibody (OX-8) is an anti-rat CD8α IgG1 monoclonal antibody. Anti-Rat CD8α Antibody (OX-8) can deplete CD8 + T cells. Anti-Rat CD8α Antibody (OX-8) can enhance airway remodeling. Anti-Rat CD8α Antibody (OX-8) can be used for researches on allergic conditions and infections such as RHV-rn1 virus infection and asthma .
|
-
- HY-P990243
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse FGL-1 Antibody (177R4) is an anti-mouse FGL-1 IgG2a monoclonal antibody. Anti-Mouse FGL-1 Antibody (177R4) can increase CD8 + T cell infiltration. Anti-Mouse FGL-1 Antibody (177R4) enhances the anti-tumor immune effect by blocking FGL1. Anti-Mouse FGL-1 Antibody (177R4) can be used for research on cancer such as lung cancer and breast cancer .
|
-
- HY-P990239
-
|
|
HSP
Akt
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonal antibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation .
|
-
- HY-P990140
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Rat β-2-Microglobulin Antibody (4C9) is an anti-rat β-2-Microglobulin IgG1 monoclonal antibody. Anti-Rat β-2-Microglobulin Antibody (4C9) reduces pJNK nuclear translocation and restore SMAD nuclear localization. Anti-Rat β-2-Microglobulin Antibody (4C9) is often used in immunoprecipitation experiments .
|
-
- HY-P990217
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived anti-mouse IL-23 p19 IgG1 monoclonal antibody. Anti-Mouse IL-23 p19 Antibody (G23-8) alleviates inflammation by restoring CLDN8 expression. Anti-Mouse IL-23 p19 Antibody (G23-8) can be used for research on inflammation conditions such as colitis and asthma .
|
-
- HY-P99149
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonal antibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for researches on inflammation conditions and cancer such as breast cancer .
|
-
- HY-P990572
-
DCBY02
1 Publications Verification
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
DCBY02 is a monoclonal antibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
|
-
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
|
-
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
-
- HY-P99050
-
|
BIVV009; IPN-009; TNT009
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
|
-
- HY-P991446
-
|
|
Influenza Virus
|
Infection
|
|
MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
|
-
- HY-P99384
-
|
B-701; MFGR-1877S; RG-7444
|
FGFR
|
Cancer
|
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9803
-
|
SARS-80R; SARS antibody-80R
|
SARS-CoV
|
Infection
|
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
-
- HY-P991395
-
|
|
Tim3
|
Cancer
|
|
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
|
-
- HY-P9805
-
|
MERS-3A1; MERS antibody-3A1
|
SARS-CoV
|
Infection
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
-
- HY-P991346
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992484
-
|
|
Tau Protein
|
Neurological Disease
|
|
VY7523 is a monoclonal antibody and a selective inhibitor of pathological Tau. VY7523 reduces the propagation of pathogenic Tau in transgenic mouse models. VY7523 can be used in the research of Alzheimer's disease. The isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P992330
-
|
KB312
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
CBT004 (KB312) is a human IgG1κ type monoclonal antibody against CD83. CD83 is a type I transmembrane glycoprotein and is a highly expressed marker on the surface of mature DCs. It can also be induced to be expressed on activated B cells, some activated T cells, and activated monocytes.
|
-
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
-
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
-
- HY-P990043
-
|
VGL101
|
Ser/Thr Kinase
TREM receptor
|
Inflammation/Immunology
|
|
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
|
-
- HY-108730A
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
|
-
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
- HY-P992404
-
|
|
TNF Receptor
|
Cancer
|
|
MDX-1401 is a fully human IgG1 (κ isotype) monoclonal antibody against CD30, with a Kd value of 0.83 nmol/L. MDX-1401 induces antibody-dependent cellular cytotoxicity in CD30-expressing cells and inhibits tumor growth in CD30 + lymphoma xenograft models. MDX-1401 can be used in research related to malignant lymphoma and Hodgkin lymphoma .
|
-
- HY-P9991
-
|
TST001
|
Gap Junction Protein
|
Cancer
|
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
-
- HY-P991253
-
|
|
IGF-1R
|
Cancer
|
|
BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991487
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
LASN01 is a human IgG1 monoclonal antibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991443
-
|
|
CD73
|
Cancer
|
|
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991491
-
|
|
SARS-CoV
Influenza Virus
|
Infection
|
|
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P991867
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991070
-
|
|
TNF Receptor
|
Cancer
|
|
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991067
-
|
KP-104
|
Complement System
|
Inflammation/Immunology
|
|
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
|
-
- HY-P990238
-
|
|
EGFR
|
Inflammation/Immunology
Cancer
|
|
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8 + T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer .
|
-
- HY-P990177
-
|
|
Notch
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse Notch4 Antibody (HMN4-14) is an anti-mouse Notch4 IgG monoclonal antibody. Anti-Mouse Notch4 Antibody (HMN4-14) reduces inflammation by restoring the expression of bispecific proteins. Anti-Mouse Notch4 Antibody (HMN4-14) can inhibit Th2/Th17 cell differentiation and improve Treg cell function. Anti-Mouse Notch4 Antibody (HMN4-14) can be used for research on inflammation conditions such as viral pneumonia and airway inflammation .
|
-
- HY-P990795
-
|
|
Osteopontin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonal antibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .
|
-
- HY-P991447
-
|
|
VISTA
|
Cancer
|
|
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990247
-
|
|
E-Selectin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse E-selectin/CD62E Antibody (9A9) is an anti-mouse E-selectin/CD62E IgG2b monoclonal antibody. Anti-Mouse E-selectin/CD62E Antibody (9A9) has an inhibitory effect on cancer cell colonization. Anti-Mouse E-selectin/CD62E Antibody (9A9) can be used for researches on inflammation conditions and cancer such as acute microvascular inflammation and breast cancer .
|
-
- HY-P991961
-
|
|
CTLA-4
|
Cancer
|
|
REGN4659 is a fully human anti-CTLA-4 monoclonal antibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice .
|
-
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
-
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
-
- HY-P99123A
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).
|
-
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
- HY-P991708
-
|
REGN-4336
|
PSMA
CD3
|
Cancer
|
|
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
|
-
- HY-P992326
-
|
|
PDGFR
|
Inflammation/Immunology
Cancer
|
|
BOT1711 is a human IgG1κ monoclonal antibody targeting PDGFRB/CD140b. PDGFRB/CD140b belongs to type I receptor tyrosine kinases (RTKs), and is mainly expressed in vascular smooth muscle cells, pericytes, fibroblasts, certain mesenchymal stem cells, and tumor stromal cells.
|
-
- HY-P9970
-
|
Avakine; CT-P13; SB2; TA-650
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
The component ratio of this product is Active ingredient : Excipients = 9 : 47.
|
-
- HY-P990937
-
|
PF-04236921; TOUR-006
|
Interleukin Related
|
Inflammation/Immunology
|
|
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
|
-
- HY-P991406
-
|
|
TNF Receptor
|
Cancer
|
|
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
|
-
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
|
-
- HY-P99268
-
|
SAR 256212; MM 121
|
EGFR
Apoptosis
|
Cancer
|
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
-
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
-
- HY-P991066
-
|
ARGX-119
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P992475
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P991636
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
|
-
- HY-P992354
-
|
INBRX-110
|
TNF Receptor
NF-κB
|
Cancer
|
|
FPA154 is a human monoclonal antibody against TNFRSF18/GITR/CD357. FPA154 activates NF-κB via the GITR pathway. FPA154 can be used in solid tumor research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991648
-
|
|
Interleukin Related
|
Cancer
|
|
CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research .
|
-
- HY-P99648A
-
|
BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
|
-
- HY-P99961
-
|
JS004; Icatolimab
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer .
|
-
- HY-P99837
-
|
SPV-T3a
|
CD3
|
Infection
|
|
Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
|
-
- HY-P992471
-
|
SYD1875 antibody
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
SYD1875 (SYD1875 Antibody) is an anti-5T4 antibody-drug conjugate (ADC) with anti-tumor potential. SYD1875 consists of a humanized IgG1 monoclonal antibody and a site-conjugated vc-seco-DUBA toxin. SYD1875 specifically binds to tumor cells that highly express carcinoembryonic antigen (CEA) 5T4, inducing apoptosis in these cells through DNA alkylation damage. SYD1875 can be used in research on aggressive tumors that highly express 5T4.
|
-
- HY-P990197
-
|
|
L-Selectin
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse MAdCAM-1 Antibody (MECA-367) is an anti-mouse MAdCAM-1 IgG2a monoclonal antibody. Anti-Mouse MAdCAM-1 Antibody (MECA-367) significantly inhibits the migration of pig peripheral blood lymphocytes (PBL) by blocking the function of MAdCAM-1. Anti-Mouse MAdCAM-1 Antibody (MECA-367) selectively inhibits B cell migration to exacerbate inflammation. Anti-Mouse MAdCAM-1 Antibody (MECA-367) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as colitis and diabetes .
|
-
- HY-P990206
-
|
|
Notch
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonal antibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE) .
|
-
- HY-P990246
-
|
|
Adhesion G Protein-coupled Receptors (AGPCRs)
|
Inflammation/Immunology
|
|
Anti-Mouse F4/80 Antibody (CI:A3-1) is an anti-mouse F4/80 IgG2b monoclonal antibody. Anti-Mouse F4/80 Antibody (CI:A3-1) can clear macrophages. Anti-Mouse F4/80 Antibody (CI:A3-1) can be used for research on inflammation conditions such as endometriosis. Anti-Mouse F4/80 Antibody (CI:A3-1) often used for flow cytometry analysis and immunohistochemical analysis .
|
-
- HY-P99132
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
|
-
- HY-P990121
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-4 Antibody (11B11) is an anti-mouse IL-4 IgG1 monoclonal antibody. Anti-Mouse IL-4 Antibody (11B11) can inhibit Th2 cell differentiation by blocking the IL-4 signaling pathway. Anti-Mouse IL-4 Antibody (11B11) can significantly reduce fibrosis combined with anti-IL13 mAb. Anti-Mouse IL-4 Antibody (11B11) can be used for researches on cancer and inflammation conditions such as colorectal cancer and prostatitis .
|
-
- HY-P990210
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse/Human IL-7 Antibody (M25) is an anti-mouse IL-7 IgG2b monoclonal antibody. Anti-Mouse/Human IL-7 Antibody (M25) alleviates inflammation by blocking IL-7 signaling and inhibiting innate lymphoid cells (ILC2s) activation. Anti-Mouse/Human IL-7 Antibody (M25) can reduce the number of B cell precursors. Anti-Mouse/Human IL-7 Antibody (M25) can be used for researches on inflammation conditions such as airway inflammation .
|
-
- HY-P990142
-
|
|
MHC
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse Vβ4 TCR Antibody (KT4) is an anti-mouse Vβ4 TCR IgG2b monoclonal antibody. Anti-Mouse Vβ4 TCR Antibody (KT4) can reduce the proportion of Vβ4 + T cells without affecting their function. Anti-Mouse Vβ4 TCR Antibody (KT4) can be used for research on immunology and infection conditions such as virus infection. Anti-Mouse Vβ4 TCR Antibody (KT4) is often used in flow cytometry .
|
-
- HY-P990204
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is a chimeric antibody of the original C9B7W antibody (HY-P99141). Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) contains the D265A mutation region. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) can be used for research on cancer .
|
-
- HY-P991995
-
|
OMTX705 antibody
|
ADC Antibody
FAP
|
Cancer
|
|
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
|
-
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
Akt
p38 MAPK
Apoptosis
|
Cancer
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
|
-
- HY-145636
-
|
AEX4089DC1; MGC018
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .
|
-
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
-
- HY-P99705
-
|
RG-7599; DNIB-0600A; NaPi2b-ADC
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .
|
-
- HY-185683
-
|
DB-1311; BNT324
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
CD276/B7-H3
|
Cancer
|
|
Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate (ADC) targeting B7H3. Elfetabart drozuntecan conjugates a humanized anti-B7H3 IgG1 monoclonal antibody with a topoisomerase I inhibitor via a cleavable linker. Elfetabart drozuntecan exerts antitumor activity in solid tumors. Elfetabart drozuntecan can be used for the research of advanced/metastatic solid tumors .
|
-
- HY-P992344
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P990866
-
|
|
Interleukin Related
|
Cancer
|
|
Anti-CD25/IL-2Rα Antibody (7G7B6) is an anti-human CD25/IL-2Rα IgG2a monoclonal antibody. Anti-CD25/IL-2Rα Antibody (7G7B6) can inhibit the growth of tumors. Anti-CD25/IL-2Rα Antibody (7G7B6) can be used for research on leukemia. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
- HY-P99828
-
|
PF-06523435; hu24
|
ADC Antibody
RET
PERK
ROR
|
Cancer
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .
|
-
- HY-P99754
-
|
BCD-085
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99119
-
|
|
TNF Receptor
Bcl-2 Family
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
|
-
- HY-P99141
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
|
-
- HY-P991363
-
|
|
Myosin
STAT
|
Inflammation/Immunology
|
|
AX-202 is a humanized IgG4 monoclonal antibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .
|
-
- HY-P99239
-
|
HUJ-591; TLX591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
-
- HY-P99203
-
|
REGN-2810; SAR-439684
|
PD-1/PD-L1
|
Cancer
|
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
-
- HY-P9957
-
|
ABthrax
|
Bacterial
|
Infection
|
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
-
- HY-P9806
-
|
MERS-D12; MERS antibody-D12
|
SARS-CoV
|
Infection
|
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
-
- HY-P991178
-
|
|
TNF Receptor
|
Cancer
|
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
-
- HY-P991532
-
|
MEMD; EJ212/007-Cl2-5
|
ALCAM/CD166
|
Inflammation/Immunology
Cancer
|
|
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
|
-
- HY-P991569
-
|
|
Wnt
|
Metabolic Disease
Endocrinology
|
|
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
|
-
- HY-P991574
-
|
REG-101
|
ATGL
|
Cardiovascular Disease
|
|
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
|
-
- HY-P991947
-
|
AFS98; TG3003
|
c-Fms
|
Inflammation/Immunology
|
|
ELB041 (AFS98) is a rat monoclonal anti-murine c-fms antibody (IgG2a). AFS98 inhibits M-CSF–dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. AFS98 prevents development of fatty streaks in ApoE-deficient mice. ELB041 can be used for the research of atherosclerosis .
|
-
- HY-P990802
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
- HY-P990796
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-P990273
-
|
|
CD38
ERK
CD1
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
|
-
- HY-P990176
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is an anti-mouse OX40/CD134 (LALA-PG) IgG2a monoclonal antibody. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is a chimeric antibody of the original OX86 antibody (HY-P990115). Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can significantly enhance the generation of antigen-specific effector T cells. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can be used for research on cancer .
|
-
- HY-P990219
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-2 Antibody (JES6-1A12) is an anti-mouse IL-2 IgG1 monoclonal antibody. Anti-Mouse IL-2 Antibody (JES6-1A12) can inhibit Treg amplification and enhance Th1 response. Anti-Mouse IL-2 Antibody (JES6-1A12) can form a complex with IL-2 for experimentation. Anti-Mouse IL-2 Antibody (JES6-1A12) can be used for research on infection conditions such as malaria .
|
-
- HY-P990141
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse Vβ8 TCR Antibody (F23.1) is an anti-mouse Vβ8 TCR IgG2a monoclonal antibody. Anti-Mouse Vβ8 TCR Antibody (F23.1) can clear Vβ8 + T cells to alleviate immune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) can be used for research on autoimmune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) is often used in flow cytometry .
|
-
- HY-P990201
-
|
|
L-Selectin
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is an anti-mouse L-Selectin/CD62L IgG2a monoclonal antibody. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can significantly inhibit the migration of T cells and B cells. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can block initial lymphocyte homing. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can be used for researches on inflammation, metabolic and infection conditions such as diabetes and parasitic infections .
|
-
- HY-P99138
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1a Antibody (ALF-161) is an anti-mouse IL-1a IgG1 monoclonal antibody. Anti-Mouse IL-1a Antibody (ALF-161) can inhibit CD8 + T cell response by blocking IL-1a signaling. Anti-Mouse IL-1a Antibody (ALF-161) can reversibly transform myeloid cell expansion and improve T cell function. Anti-Mouse IL-1a Antibody (ALF-161) can be used for researches on immune response and cancer such as breast cancer .
|
-
- HY-P990250
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-Mouse DKK3 Antibody (DKK3-4.22) is an anti-mouse DKK3 IgG1 monoclonal antibody. Anti-Mouse DKK3 Antibody (DKK3-4.22) can improve kidney function and increases T cell infiltration. Anti-Mouse DKK3 Antibody (DKK3-4.22) can reduce skin inflammation by blocking the immunosuppressive function of DKK3. Anti-Mouse DKK3 Antibody (DKK3-4.22) can be used for researches on inflammation conditions such as unilateral ureteral obstruction (UUO) and experimental autoimmune encephalomyelitis (EAE) .
|
-
- HY-P99051
-
|
BAY 1834942
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
|
-
- HY-P99643
-
|
UCB6114
|
Dan family
|
Cancer
|
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
-
- HY-P99389
-
|
JNJ-64304500; IPH-2301; NN-8555
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D, with a KD value of 9.2 pM . Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease .
|
-
- HY-P991957
-
|
|
Prion Protein
|
Neurological Disease
|
|
PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.
|
-
- HY-P9970A
-
|
Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
|
-
- HY-P991247
-
|
|
MHC
|
Cancer
|
|
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
- HY-E70364
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .
|
-
- HY-P99525
-
|
R 84 (antibody); GNR-011
|
VEGFR
|
Cancer
|
|
Varisacumab (R 84; GNR-011) is a fully humanized IgG1 monoclonal antibody targeting VEGF. Varisacumab specifically blocks the interaction between VEGF and VEGFR2, but does not interfere with the interaction between VEGF and VEGFR1. Varisacumab achieves effective anti-tumor and anti-angiogenic effects and can be used in the research of non-small cell lung cancer and pancreatic cancer.
|
-
- HY-P991557
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
ABI793 is a human IgG1 anti-human CD154 (CD40 ligand) monoclonal antibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection .
|
-
- HY-P99650
-
|
WT1
|
Transmembrane Glycoprotein
|
Cancer
|
|
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .
|
-
- HY-P991653
-
|
|
CCR
HIV
|
Infection
|
|
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
|
-
- HY-P990236
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonal antibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .
|
-
- HY-P990157
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is an anti-mouse Thy1/CD90 IgG2a monoclonal antibody. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can clear T cells from the spleen and bone marrow. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can be used for researches on immunology and inflammation conditions such as colitis .
|
-
- HY-P99126
-
|
|
Transmembrane Glycoprotein
CD44
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma .
|
-
- HY-P990249
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer .
|
-
- HY-P990680
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
|
-
- HY-P99045
-
|
HRS7; hRS7
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
- HY-P992176
-
|
|
CD47
|
Cancer
|
|
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10 -9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .
|
-
- HY-P990180
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonal antibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8 + T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma .
|
-
- HY-P990208
-
|
|
Interleukin Related
NF-κB
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-9 Antibody (9C1) is an anti-mouse IL-9 IgG2a monoclonal antibody. Anti-Mouse IL-9 Antibody (9C1) can reduce the activation of NF-κB signaling pathway and decrease the infiltration of inflammatory cells. Anti-Mouse IL-9 Antibody (9C1) effectively reduces Th9 cell-mediated allergic reactions and anti-tumor effects. Anti-Mouse IL-9 Antibody (9C1) can be used for researches on inflammation, infection conditions and cancer such as parasitic infections, allergic reactions, breast cancer and osteosarcoma .
|
-
- HY-P990196
-
|
|
P-glycoprotein
|
Cancer
|
|
Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is an anti-monkey/human MDR-1/CD243 IgG2a monoclonal antibody. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can efficiently inhibit P-glycoprotein. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) enhances the inhibitory effect on multidrug resistance (MDR) by suppressing drug efflux. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can be used for research on cancer .
|
-
- HY-P990165
-
|
|
RANKL/RANK
E1/E2/E3 Enzyme
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonal antibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis .
|
-
- HY-P990123
-
|
|
Transmembrane Glycoprotein
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
|
-
- HY-P99229
-
|
XMT-1535; Upinitatug
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991402
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
|
-
- HY-P9931
-
|
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
-
- HY-164957
-
|
SGN-B6A; PF-08046047
|
Antibody-Drug Conjugates (ADCs)
Integrin
|
Cancer
|
|
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .
|
-
- HY-P991214
-
|
EMD 273066; huKS-IL2
|
Interleukin Related
|
Cancer
|
|
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .
|
-
- HY-P99190
-
|
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
-
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
|
-
- HY-P9907
-
Trastuzumab
Maximum Cited Publications
55 Publications Verification
Anti-Human HER2, Humanized antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
|
-
- HY-P99391
-
|
ABT-700; ABBV-400 antibody
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
- HY-P991651
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
|
-
- HY-P992450
-
|
|
TNF Receptor
|
Cancer
|
|
REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
|
-
- HY-P990198
-
|
|
Galectin
|
Inflammation/Immunology
|
|
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonal antibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry .
|
-
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99045A
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
- HY-P991229
-
|
AGS-1C4D4; AGS-PSCA
|
Complement System
|
Cancer
|
|
AGS-1C4D4 is a fully human IgG1κ monoclonal antibody targeting PSCA, with a Kd value of 0.2 nM. AGS-1C4D4 mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against PSCA-expressing cells. AGS-1C4D4 can be used for the research of pancreatic cancer .
|
-
- HY-P991892A
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
|
-
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
-
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9971
-
|
SHR-1210; INCSHR1210
|
PD-1/PD-L1
|
Cancer
|
|
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
|
-
- HY-P991599
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990212
-
|
|
Interleukin Related
STAT
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonal antibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
|
-
- HY-P990248
-
|
|
Cadherin
EGFR
PERK
Akt
mTOR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonal antibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma .
|
-
- HY-P990134
-
|
|
TNF Receptor
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD40L/CD154 Antibody (MR-1) is an anti-mouse CD40L/CD154 IgG monoclonal antibody. Anti-Mouse CD40L/CD154 Antibody (MR-1) reduces the expression of IFN signaling pathway and lowers the level of IFN-β. Anti-Mouse CD40L/CD154 Antibody (MR-1) can prolong the survival time of transplants. Anti-Mouse CD40L/CD154 Antibody (MR-1) can be used for researches on cancer, inflammation conditions and xenotransplantation such as pancreatic cancer and autoimmune cholangitis .
|
-
- HY-P990214
-
|
|
Interleukin Related
Parasite
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-3 Antibody (MP2-8F8) is an anti-mouse IL-3 IgG1 monoclonal antibody. Anti-Mouse IL-3 Antibody (MP2-8F8) relieves joint inflammation by reducing synovial leukocyte infiltration and cytokine levels. Anti-Mouse IL-3 Antibody (MP2-8F8) can reduce the accumulation of basophils. Anti-Mouse IL-3 Antibody (MP2-8F8) can be used for researches on inflammation or infection conditions such as arthritis and parasitic infections .
|
-
- HY-P990001
-
|
|
Interleukin Related
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .
|
-
- HY-P990115
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 + T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .
|
-
- HY-P99055
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
-
- HY-P991620
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
|
-
- HY-P99248
-
|
Risankizumab rzaa; BI 655066; ABBV-066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
-
- HY-P991534
-
|
|
Amyloid-β
|
Neurological Disease
|
|
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
|
-
- HY-P991452
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonal antibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990151
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is an anti-mouse TL1A/TNFSF15 IgG monoclonal antibody. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can reduce TL1A levels and block TL1A-DR3 interactions. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can be used for research on inflammation conditions such as colitis and collagen-induced arthritis (CIA) .
|
-
- HY-P990160
-
|
|
MHC
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Rat TCR alpha/beta Antibody (R73) is an anti-mouse TCR alpha/beta IgG1 monoclonal antibody. Anti-Rat TCR alpha/beta Antibody (R73) suppresses immune response by depleting α/β + T cells. Anti-Rat TCR alpha/beta Antibody (R73) can inhibit the expression of pro-inflammatory cytokines. Anti-Rat TCR alpha/beta Antibody (R73) can extend graft survival time by reducing infiltration of T cells and neutrophils. Anti-Rat TCR alpha/beta Antibody (R73) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as arthritis, acute inflammatory peripheral neuropathy and diabetes .
|
-
- HY-145644
-
|
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
-
- HY-P99391A
-
|
ABT-700 (powder)
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
- HY-P990952
-
|
OMS906
|
Ser/Thr Protease
Complement System
|
Metabolic Disease
Inflammation/Immunology
|
|
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .
|
-
- HY-P990061
-
|
JTX 8064
|
LILRB
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
|
-
- HY-P991310
-
|
LT3015; LT-3000
|
LPL Receptor
|
Neurological Disease
Cancer
|
|
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-185460
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
PI3K
mTOR
|
Cancer
|
|
Pertuzumab-LD3 is a humanized antibody-drug conjugate (ADC) targeting HER2. Pertuzumab-LD3 consists of the anti-HER2 humanized IgG1 monoclonal antibody Pertuzumab (HY-P9912), the cleavable linker Gly-Gly-Phe-Gly (HY-P3669), and the PI3K/mTOR-IN-21 (HY-185456) payload. Pertuzumab-LD3 can be used in research on metastatic HER2-positive breast cancer.
|
-
- HY-185483
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
Microtubule/Tubulin
|
Cancer
|
|
AMG-172 is an antibody-drug conjugate (ADC) composed of a fully human IgG1 monoclonal anti-CD27L antibody conjugated to DM1 (HY-19792) via the non-cleavable linker MCC. AMG-172 releases the intracellular active component Lysine-MCC-DM through catabolism. Lysine-MCC-DM inhibits the assembly and disassembly dynamics of Microtubule and induces cell arrest at metaphase. AMG-172 can be used for research on relapsed/refractory clear cell renal cell carcinoma .
|
-
- HY-P992447
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .
|
-
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
-
- HY-P990193
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is an anti-mouse MHC Class I (H-2Kd, H-2Dd) IgG2a monoclonal antibody. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can block the interaction between Ly49 and MHC-I. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can be used for the construction of acute lung injury models .
|
-
- HY-P990161
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonal antibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer .
|
-
- HY-P990781
-
-
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
-
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
-
- HY-P99340
-
|
VIR 7831; GSK-4182136
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
- HY-P991888
-
|
|
STAT
|
Cardiovascular Disease
Cancer
|
|
INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (KD = 1.75 nM for mutCALR del52; KD = 6.78 nM for mutCALR ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .
|
-
- HY-P992453
-
|
MTBT1466A; RG-6315
|
TGF-β Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
RO-7303509 (MTBT1466A; RG-6315) is a human monoclonal antibody and TGFβ3 neutralizer. RO-7303509 targets the profibrotic mediator TGFβ3 to alleviate fibrosis. RO-7303509 can be administered via subcutaneous or intravenous routes and is used in research on systemic sclerosis . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
-
- HY-P991654
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
|
-
- HY-P990801
-
|
|
Integrin
Parasite
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonal antibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-P990255
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 + cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer .
|
-
- HY-P990254
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
|
-
- HY-P990156
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) is an anti-mouse Thy1.1/CD90.1 IgG2a monoclonal antibody. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can deplete CD90.1 + cells. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can clear Tregs. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can be used for researches on inflammation conditions and immune response such as airway inflammation and experimental autoimmune encephalomyelitis (EAE) .
|
-
- HY-P990127
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse CD80/B7-1 IgG2a monoclonal antibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (TRM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant .
|
-
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
- HY-P990242
-
|
|
Galectin
TNF Receptor
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
|
-
- HY-P990132
-
|
|
CD47
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
|
-
- HY-P990237
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
|
-
- HY-P99121
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .
|
-
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990091
-
|
SAR 445088
|
Complement System
Fc Receptor (FcR)
|
Neurological Disease
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P9974
-
|
OMP-18R5
|
Wnt
|
Cancer
|
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
-
- HY-P991475
-
|
|
Transmembrane Glycoprotein
NF-κB
IFNAR
|
Cancer
|
|
MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991883
-
|
Licartin; Metuximab; Mehuzumab
|
Apoptosis
CDK
Caspase
Bcl-2 Family
|
Cancer
|
|
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].
|
-
- HY-P991430
-
|
TB-403
|
VEGFR
|
Cancer
|
|
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
|
-
- HY-P991633
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
|
-
- HY-P991069
-
|
|
HIV
|
Infection
|
|
VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection .
|
-
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
-
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
IFNAR
|
Cancer
|
|
Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
|
-
- HY-P991220
-
|
|
TREM receptor
|
Neurological Disease
|
|
AL002 is a humanized monoclonal IgG1 antibody and a blood-brain barrier-permeable TREM2 modulator. AL002 binds to TREM2 on the surface of microglia, promotes TREM2 clustering and the formation of the TREM2-DAP12 complex, activates the TREM2 signaling pathway and PI3K cascade, and induces TREM2 internalization and degradation. AL002 is applicable to research related to Alzheimer's disease .
|
-
- HY-P991609
-
|
|
MMP
|
Cancer
|
|
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
|
-
- HY-P991553
-
|
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
|
-
- HY-P991572
-
|
|
EGFR
|
Cancer
|
|
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
|
-
- HY-P99780
-
|
BIIB033
|
Transmembrane Glycoprotein
|
Neurological Disease
Inflammation/Immunology
|
|
Opicinumab (BIIB033) is a human IgG1 monoclonal antibody targeting LINGO-1. Opicinumab binds LINGO-1 to block its negative regulatory signaling, suppress axonal degeneration, enhance axonal regeneration, promote remyelination, and exert neuroprotective effects. Opicinumab maintains axonal protective effects during co-administration with methylprednisolone. Opicinumab can be used for the research of multiple sclerosis, acute optic neuritis, and optic neuritis. .
|
-
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
-
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P99242
-
|
|
CD276/B7-H3
|
Cancer
|
|
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
|
-
- HY-P991720
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
|
-
- HY-P991365
-
|
|
Transmembrane Glycoprotein
|
Endocrinology
|
|
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
|
-
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
-
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
- HY-P990131
-
|
|
CD47
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
|
-
- HY-P990004
-
|
|
Tim3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
|
-
- HY-P99125
-
|
|
Fc Receptor (FcR)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .
|
-
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Neurological Disease
|
|
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
|
-
- HY-P99146
-
|
|
CD3
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) is an anti-mouse TCR gamma/delta IgG monoclonal antibody. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can enter the blood-brain barrier. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) effectively depletes γδ T cells and reduces macrophage and neutrophil infiltration. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can reduce the immune response of transplants. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can be used for researches on inflammation conditions, virus infection and cancer such as arthritis, JHM virus and breast cancer .
|
-
- HY-P992212
-
|
|
L-Selectin
|
Inflammation/Immunology
|
|
Anti-CD62L Antibody (DREG-200) is a human monoclonal antibody targeting CD62L/L-selectin. Anti-CD62L Antibody (DREG-200) binds to residues 45, 46 and 47 of L-selectin, and blocks L-selectin-mediated interactions, neutrophil rolling, adhesion, aggregation, secondary anchoring, as well as leukocyte rolling on ligands. Anti-CD62L Antibody (DREG-200) reduces myocardial necrosis, coronary endothelial dysfunction, and neutrophil migration driven by neutrophil microparticles. Anti-CD62L Antibody (DREG-200) exerts cardioprotective effects in feline models. Anti-CD62L Antibody (DREG-200) can be used in studies related to myocardial ischemia-reperfusion injury. The recommended isotype control is Mouse IgG1 kappa (HY-P99977) .
|
-
- HY-P991611
-
|
|
iGluR
|
Inflammation/Immunology
|
|
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
|
-
- HY-P991960
-
|
|
CTLA-4
Interleukin Related
|
Cancer
|
|
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
|
-
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
- HY-P991864
-
|
MDX-124
|
Formyl Peptide Receptor (FPR)
|
Cancer
|
|
Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma .
|
-
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
- HY-P99613
-
|
MK-4280; Mavezelimab
|
LAG-3
|
Cancer
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990661
-
|
|
c-Met/HGFR
ERK
PERK
|
Cancer
|
|
SAIT-301 is a Met-targeting monoclonal antibody. SAIT-301 inhibits Met activation, induces downregulated expression of phosphorylated Met(p-Met) and phosphorylated ERK(p-ERK), and reduces EGR-1 expression. SAIT-301 inhibits the migration and invasion of nasopharyngeal carcinoma cells. SAIT-301 is applicable to relevant research on nasopharyngeal carcinoma. For the isotype control of SAIT-301, refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992053
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-CD11a Antibody (MHM24) is a monoclonal antibody targeting murine CD11a. Anti-CD11a Antibody (MHM24) binds to high-affinity (open) and low-affinity (closed) conformations of the αL subunit of LFA-1, and functionally blocks LFA-1-mediated interactions. Anti-CD11a Antibody (MHM24) blocks ICAM-1 binding to LFA-1-expressing cells. Anti-CD11a Antibody (MHM24) inhibits adhesion of high-affinity LFA-1-expressing cells to keratinocytes. Anti-CD11a Antibody (MHM24) inhibits PHA-induced lymphocyte proliferation. Anti-CD11a Antibody (MHM24) can be used for the research of inflammatory and autoimmune diseases. Recommend Isotype Controls: mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
-
- HY-P991950
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9980
-
|
GSK2857914
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
|
-
- HY-P990114
-
|
|
PD-1/PD-L1
|
Others
|
|
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .
|
-
- HY-P990294
-
|
|
Transmembrane Glycoprotein
STAT
Collagen
Reactive Oxygen Species (ROS)
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis .
|
-
- HY-P990253
-
|
|
Notch
EAAT
|
Inflammation/Immunology
|
|
Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) is an anti-mouse Delta-like protein 1/DLL1 IgG monoclonal antibody. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can reverse the inhibition of Treg cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can inhibit the upregulation of GLT-1 expression induced by endothelial cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) reduces autoimmune response by reducing B cell activation. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can be used for research on inflammation conditions such as lupus nephritis .
|
-
- HY-P990175
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonal antibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4 + T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC) .
|
-
- HY-P99959
-
|
MT-3921; rH116A3
|
TGF-β Receptor
|
Neurological Disease
|
|
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
|
-
- HY-P991567
-
|
VX5/5261
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
|
-
- HY-P99952
-
|
SCT400
|
CD20
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
|
-
- HY-145642
-
|
ZRC3308-A7
|
SARS-CoV
|
Infection
|
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
|
-
- HY-P991958
-
|
|
CTLA-4
|
Cancer
|
|
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
|
-
- HY-P99646
-
|
MEDI6570
|
LOX-1
|
Metabolic Disease
Inflammation/Immunology
|
|
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .
|
-
- HY-P991671
-
|
JNJ-80948543
|
CD3
CD20
Transmembrane Glycoprotein
|
Cancer
|
|
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
|
-
- HY-P991364
-
|
PYX-106; BSI-060T
|
Transmembrane Glycoprotein
|
Cancer
|
|
Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
|
-
- HY-145643
-
|
ZRC3308-B10
|
SARS-CoV
|
Infection
|
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-P992151
-
|
LT1002
|
LPL Receptor
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a Kd value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .
|
-
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
Bacterial
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
-
- HY-P991515
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
|
-
- HY-P9964
-
|
11F8; IMC-11F8; LY3012211
|
EGFR
|
Cancer
|
|
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
|
-
- HY-P990297
-
|
|
CCR
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
|
-
- HY-P990279
-
|
|
CD276/B7-H3
Apoptosis
STAT
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
|
-
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
-
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
-
- HY-P991551
-
|
|
Dipeptidyl Peptidase
p38 MAPK
ERK
|
Infection
Cancer
|
|
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
|
-
- HY-P99008
-
|
IC14
|
Toll-like Receptor (TLR)
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
|
-
- HY-P991424
-
|
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991598
-
|
MOR12743; MOR03207
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
|
-
- HY-P99027
-
|
LAG525; IMP701; Hu5A8
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
|
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
-
- HY-P11084A
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P990144
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
|
-
- HY-P992381
-
|
|
Drug Derivative
|
Cancer
|
|
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
|
-
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
-
- HY-P991656
-
|
|
CXCR
Apoptosis
p38 MAPK
Akt
|
Cancer
|
|
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
|
-
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
-
- HY-P991468
-
|
|
Interleukin Related
|
Cancer
|
|
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991855
-
|
|
TGF-β Receptor
|
Metabolic Disease
|
|
RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a KD of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation .
|
-
- HY-P991444
-
|
|
NTPDase
ATP Synthase
|
Inflammation/Immunology
Cancer
|
|
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .
|
-
- HY-P991584
-
|
|
FGFR
|
Cancer
|
|
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
|
-
- HY-P990690
-
|
MEDI-5752
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
|
-
- HY-P992413
-
|
|
Integrin
|
Inflammation/Immunology
|
|
MOR102 is a fully human IgG4 monoclonal antibody and an ICAM-1 inhibitor, lacking cross-reactivity with ICAM-2 and ICAM-3. MOR102 binds to the LFA-1 binding site within ICAM-1 domain 1, blocks ICAM-1/LFA-1 interaction, binds human keratinocytes with increased binding to interferon-γ-stimulated keratinocytes. MOR102 inhibits lymphocyte adhesion, reduces lymphocyte proliferation, prevents local T-cell activation, reduces inflammatory infiltrate, restores orthokeratotic differentiation, and reduces epidermal thickness. MOR102 can be used for the research of psoriasis .
|
-
- HY-P992335
-
|
|
Interleukin Related
|
Cancer
|
|
COM503 is a high-affinity anti-IL18BP human monoclonal antibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
-
- HY-P990252
-
|
|
Notch
Interleukin Related
NF-κB
VEGFR
FGFR
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .
|
-
- HY-P992437
-
|
|
CD44
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .
|
-
- HY-P991927
-
|
|
CD47
|
Cancer
|
|
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
|
-
- HY-P992382
-
|
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003 .
|
-
- HY-P99014
-
|
ARGX-110
|
Fc Receptor (FcR)
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
|
-
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
-
- HY-P99048A
-
|
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P99390
-
|
MCLA 117
|
CD3
Interleukin Related
IFNAR
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
|
-
- HY-P990951
-
|
REGN-5381
|
Natriuretic Peptide Receptor (NPR)
|
Cardiovascular Disease
|
|
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .
|
-
- HY-P991000
-
|
AU-007; BD-8; BDG8
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99750
-
|
CT-P23
|
Influenza Virus
|
Infection
|
|
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
|
-
- HY-P991381
-
|
PPMX-T003
|
Transferrin Receptor
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cancer
|
|
JST‑TfR09 (PPMX‑T003) is a human monoclonal antibody (mAb) targeting transferrin receptor 1 (TfR1/CD71). JST‑TfR09 blocks the binding of transferrin to TfR1, inhibits TfR1 internalization, and suppresses cellular iron uptake. JST‑TfR09 triggers ferritin degradation via activating the autolysosomal system, promotes ROS production and lipid peroxidation, and ultimately induces ferroptosis. JST‑TfR09 exhibits cytotoxicity toward human erythroblasts differentiated from hematopoietic stem cells. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
-
- HY-P992390
-
|
|
CD3
|
Inflammation/Immunology
|
|
IOR-T3 is a monoclonal antibody targeting CD3, with biological activities related to T cell activation regulation . IOR-T3 uses its variable region to competitively engage surface CD3 on lymphocytes and trigger robust T cell proliferation and activation. IOR-T3 and its derivatives can be used in studies related to acute transplant rejection .
|
-
- HY-177442
-
|
DS-3939
|
Antibody-Drug Conjugates (ADCs)
Mucin
Topoisomerase
Apoptosis
|
Cancer
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-P991959
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
JMW-3B3 is a humanized IgG1λ monoclonal antibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.
|
-
- HY-P992410
-
|
|
PAI-1
TGF-beta/Smad
|
Inflammation/Immunology
|
|
MEDI-579 is a fully human monoclonal antibody against PAI-1, with a KD value of 6 pM for human PAI-1 and 105 pM for rat PAI-1. MEDI-579 restores renal plasmin activity and inhibits PAI-1-mediated intracellular signal transduction. MEDI-579 reduces albuminuria, glomerulosclerosis severity, TGF-β1 expression level, and phosphorylated Smad2 level induced in diabetic mice. MEDI-579 decreases the levels of active PAI-1 in plasma and kidneys, and increases plasma plasmin level in a mouse model of lupus nephritis. MEDI-579 can be used in research related to diabetic nephropathy and lupus nephritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P9996
-
|
LY3434172; IBI-318
|
PD-1/PD-L1
|
Cancer
|
|
Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer .
|
-
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
|
-
- HY-108831A
-
|
AN100226; BG00002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
|
-
-
- HY-164153
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-164152A
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-132253
-
|
|
Fluorescent Dyes
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-164152
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-171265
-
|
MRG003
|
Fluorescent Dyes
|
|
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
|
-
- HY-177442
-
|
DS-3939
|
Fluorescent Dyes
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-132253A
-
|
|
Fluorescent Dyes
|
|
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-164154
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-D3274
-
|
|
Fluorescent Dyes
|
|
PE-Cy5 is a tandem fluorescent dye commonly used in flow cytometry, immunofluorescence, and cell biology research. It is formed by the covalent linkage of two fluorescent molecules, namely phycoerythrin and CY5. PE-Cy5 binds to human FcγRI (CD64), and this binding can be blocked by human pooled serum, anti-CD64 monoclonal antibodies targeting the ligand-binding region, or aggregated IgG. PE-Cy5 supports three-color flow cytometry analysis, and whole blood staining can partially reduce its non-specific binding (Ex/Em = 450-500 nm/665 nm) .
|
| Cat. No. |
상품명 |
Target |
Research Area |
-
- HY-P3203A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P3149
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P3149B
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P3203
-
-
- HY-P3149A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α .
|
-
- HY-P11084A
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-K0214
-
|
|
|
MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.
|
-
- HY-K0213
-
5 Publications Verification
|
|
MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.
|
| Cat. No. |
상품명 |
Target |
Research Area |
Image |
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
(5)
-
- HY-P9908
-
-
(5)
-
- HY-P99001
-
-
(5)
-
- HY-P99003
-
-
(5)
-
- HY-P9906A
-
|
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
-
(5)
-
- HY-P9909
-
-
(5)
-
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
(5)
-
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
(5)
-
- HY-P99002
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Human IgG2 kappa, Isotype Control is a human monoclonal antibody serving as an isotype control for human IgG2κ antibodies such as Cepeprubart (HY-P990732) and Ersodetug (HY-P990712). Human IgG2 kappa, Isotype Control can be used in T cell research .
|
-
(5)
-
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
(5)
-
- HY-P99979
-
-
(5)
-
- HY-P991045
-
|
mE8‑IgG2a
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (Mouse IgG2a) (mE8-IgG2a) is a mouse-derived IgG2 monoclonal antibody used in the research of Alzheimer's disease.
|
-
(5)
-
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
(5)
-
- HY-P99451
-
-
(5)
-
- HY-P990096
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Human IgG1 lambda2, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1λ antibody. Isotype control antibodies can help remove non-specific signals from experimental results and assess the accuracy and reliability of the experiment .
|
-
(5)
-
- HY-P99936
-
|
LJM716
|
EGFR
|
Cancer
|
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
-
(5)
-
- HY-P991206
-
-
(5)
-
- HY-P99982
-
-
(5)
-
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P99457
-
-
(5)
-
- HY-P99155
-
|
2F8; HUMAX-EGFR
|
EGFR
|
Cancer
|
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
-
(5)
-
- HY-P99108
-
-
(5)
-
- HY-P990100
-
-
(5)
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
(5)
-
- HY-P99305
-
-
(5)
-
- HY-P99981
-
-
(5)
-
- HY-P990713
-
-
(5)
-
- HY-P991197
-
|
LM-305 antibody; AZD-0305 antibody
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
(5)
-
- HY-P990689
-
-
(5)
-
- HY-P991207
-
-
(5)
-
- HY-P99643A
-
|
|
Dan family
|
Cancer
|
|
Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonal antibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
|
-
(5)
-
- HY-P990699
-
-
(5)
-
- HY-P990734
-
-
(5)
-
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P99347
-
-
(5)
-
- HY-P990767
-
-
(5)
-
- HY-P991164
-
|
AZD5335 antibody; INT-019
|
Antifolate
|
Inflammation/Immunology
|
|
Torvutatug is an anti-FOLR1 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P99034
-
-
(5)
-
- HY-P991190
-
-
(5)
-
- HY-P991175
-
-
(5)
-
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P990728
-
|
SP-7219; STRO-001 antibody
|
CD74
|
Inflammation/Immunology
|
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P990729
-
|
VB-119
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P990687
-
-
(5)
-
- HY-P990712
-
|
RZ-358; XOMA 358
|
Insulin Receptor
|
Inflammation/Immunology
|
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
(5)
-
- HY-P990737
-
|
LY-3041658
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
-
- HY-P99980
-
-
(5)
-
- HY-P99709
-
|
LY3300054
|
PD-1/PD-L1
|
Cancer
|
|
Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody .
|
-
(5)
-
- HY-P99635
-
|
GZ-402668
|
NF-κB
|
Cancer
|
|
Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody .
|
-
(5)
- HY-P990755
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Pamvatamig is an anti-EGFR/MET human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990760
-
-
(5)
- HY-P990747
-
|
CM-313
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99155A
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
|
-
(5)
- HY-P991743
-
|
|
Ras
|
Others
|
|
Anti-KRAS Antibody is a human-derived IgG1 kappa monoclonal antibody against KRAS.
|
-
(5)
- HY-P991559
-
|
VB6-008 antibody; VB1-008
|
CD44
|
Cancer
|
|
Anti-CD44 Antibody (VB6-008 antibody) is an IgG1 monoclonal antibody against CD44, which can be used in the study of cancer .
|
-
(5)
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990143
-
|
|
LDLR
|
Others
|
|
Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) is an anti-mouse/rat/bovine VLDL-R IgG1 monoclonal antibody. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can specifically recognize VLDLR type-I and type-II expressed in CHO cells. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) can be used to detect the expression of VLDLR in different cells and tissues. Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) often used in western blot experiments .
|
-
(5)
- HY-P99985
-
-
(5)
- HY-P991111
-
-
(5)
- HY-P99663
-
|
AMG-994
|
TNF Receptor
|
Cancer
|
|
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .
|
-
(5)
- HY-P990727
-
-
(5)
- HY-P99324
-
|
Anti-Human EGFR Recombinant antibody; CetuxiMab-GEX, GEXMab52201
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
-
(5)
- HY-P9S0062
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) can be used in research related to ulcerative colitis .
|
-
(5)
- HY-P99495
-
|
RWJ 49004
|
HIV
|
Inflammation/Immunology
|
|
Cedelizumab (RWJ 49004) is a IgG4 monoclonal antibody targeting CD4. Cedelizumab has immunosuppressant properties .
|
-
(5)
- HY-P99200
-
-
(5)
- HY-P990147
-
|
|
VEGFR
|
Others
|
|
Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is an anti-mouse VEGFR-2 IgG2a monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is a chimeric antibody of the original DC101 antibody (HY-P990106). Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) can react with mouse VEGFR-2 .
|
-
(5)
- HY-P991166
-
|
|
Mucin
|
Others
|
|
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P990030
-
-
(5)
- HY-P991169
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991502
-
-
(5)
- HY-P99984
-
-
(5)
- HY-P990683
-
-
(5)
- HY-P99319
-
-
(5)
- HY-P991177
-
|
RC-108 antibody
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99447
-
|
ASN-1
|
Bacterial
|
Infection
|
|
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
|
-
(5)
- HY-P991165
-
|
KVA-12123; KVA-12.1
|
Fc Receptor (FcR)
|
Others
|
|
Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990746
-
-
(5)
- HY-P990754
-
|
M-1224
|
c-Kit
|
Inflammation/Immunology
|
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990749
-
|
AK-115
|
Trk Receptor
|
Inflammation/Immunology
|
|
Luvagrobart is an anti-NGF human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990229
-
|
|
Inhibitory Antibodies
|
Infection
Neurological Disease
|
|
Anti-Rat IgG2b Antibody (RG7/11.1) is an anti-rat IgG2b monoclonal antibody. Anti-Rat IgG2b Antibody (RG7/11.1) can be used for research on neurological and infection conditions such as temporal lobe epilepsy (TLE). Anti-Rat IgG2b Antibody (RG7/11.1) is often used for the same type control .
|
-
(5)
- HY-P990739
-
|
BA-3071
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991117
-
|
REGN-9933
|
Factor Xa
|
Cardiovascular Disease
|
|
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P990775
-
|
XTX101
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991340
-
|
|
PAI-1
|
Cardiovascular Disease
|
|
CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P990768
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992377
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
HY-0102 is a humanized IgG anti-NKG2A monoclonal antibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors .
|
-
(5)
- HY-P992443
-
-
(5)
- HY-P992110
-
|
DB-1311 antibody; BNT324 antibody
|
CD276/B7-H3
|
Cancer
|
|
Elfetabart (DB-1311 Antibody; BNT324 Antibody) is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992117
-
|
DCSZ-11
|
Complement System
|
Cancer
|
|
Lexucitug (DCSZ-11) is a humanized monoclonal antibody targeting CD93. The antibody isotype of Lexucitug is human IgG1κ; the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990732
-
-
(5)
- HY-P990772
-
-
(5)
- HY-P992122
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Olevaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata .
|
-
(5)
- HY-P992337
-
|
|
ROR
|
Cancer
|
|
CS5001 Antibody is an IgG1 human monoclonal antibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P990744
-
-
(5)
- HY-P992116
-
|
|
TAM Receptor
|
Cancer
|
|
Ladarutatug is a humanized monoclonal antibody targeting Tyrosine-protein kinase receptor UFO. The Ladarutatug antibody isotype is human IgG4κ; the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992115
-
|
|
Integrin
|
Cancer
|
|
Furtisetabart is a humanized monoclonal antibody targeting CD147 with anti-tumor activity. Furtisetabart is of the human IgG4κ antibody subtype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992203
-
|
|
CD47
|
Others
|
|
Anti-CD172a Antibody (3F9) is a humanized IgG1 monoclonal antibody targeting SIRPα/CD172a. The recommended isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P992118
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Lifonebart is a humanized monoclonal antibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990696
-
-
(5)
- HY-P990725
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991116
-
-
(5)
- HY-P990705
-
|
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990773
-
|
LY-3361237
|
CD28
|
Inflammation/Immunology
|
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P99267
-
|
RhuMab IFNalpha; Anti-Human IFN alpha Recombinant antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].
|
-
(5)
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized antibody; LDP-02; MLN-002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
(5)
- HY-P991191
-
-
(5)
- HY-P992184
-
|
ASN004 antibody
|
Wnt
|
Cancer
|
|
Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) is a human IgG1 monoclonal antibody targeting TPBG. Anti-5T4 scFv-Fc Antibody (ASN004 Antibody) can be used in cancer research. The recommended isotype control is human IgG1 kappa (HY-P99001).
|
-
(5)
- HY-P991187
-
|
AGX-101 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990684
-
-
(5)
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
-
(5)
- HY-P991170
-
|
|
SARS-CoV
|
Infection
|
|
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990771
-
|
INCA-00186
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990769
-
-
(5)
- HY-P991422
-
-
(5)
- HY-P990764
-
|
SGN-B6A antibody
|
Integrin
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonal antibody against ITGB6.
Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957) .
|
-
(5)
- HY-P991106
-
|
LY-3076226 antibody
|
FGFR
|
Cancer
|
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990244
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) effectively inhibits the binding of FcRn to IgG. Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is used in studies of the MHC class I heavy chain FcRn heterodimers and their interaction with IgG .
|
-
(5)
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
(5)
- HY-P991188
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MGD007 is a humanized IgG1 monoclonal antibody targeting GPA33. MGD007 can be used for study of Metastatic Colorectal Cancer .
|
-
(5)
- HY-P99724
-
-
(5)
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
(5)
- HY-P992230
-
|
|
Neuropeptide Y Receptor
|
Inflammation/Immunology
|
|
Anti-Galanin Antibody is a monoclonal antibody that targets galanin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Galanin Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
(5)
- HY-P992272
-
|
|
Lipocalin Family
|
Inflammation/Immunology
|
|
Anti-NGAL Antibody is a monoclonal antibody targeting NGAL. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGAL Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992296
-
|
|
PTHR
|
Inflammation/Immunology
|
|
Anti-PTHrP Antibody is a monoclonal antibody that targets PTHrP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PTHrP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992294
-
|
|
Prion Protein
|
Inflammation/Immunology
|
|
Anti-PRNP Antibody is a monoclonal antibody that targets PRNP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRNP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992285
-
-
(5)
- HY-P992256
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
Anti-LCAT Antibody is a monoclonal antibody targeting LCAT. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LCAT Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
(5)
- HY-P992271
-
|
|
GDNF Receptor
|
Inflammation/Immunology
|
|
Anti-Neublastin Antibody is a monoclonal antibody targeting neublastin. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Neublastin Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P992190
-
|
|
Apelin Receptor (APJ)
|
Inflammation/Immunology
|
|
Anti-Apelin Antibody is a monoclonal antibody that targets apelin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-Apelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992234
-
|
|
Glycosidase
|
Inflammation/Immunology
|
|
Anti-Heparanase Antibody is a monoclonal antibody that targets heparanase. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-heparanase antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990726
-
|
KPL-404
|
TNF Receptor
|
Inflammation/Immunology
|
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P990743
-
|
AB023; Xisomab 3G3; MAB 14E11
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Gruticibart is an anti-F11 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P990750
-
|
IBI-110
|
LAG-3
|
Inflammation/Immunology
|
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992290
-
|
|
SHP1
|
Inflammation/Immunology
|
|
Anti-PILRA Antibody is a monoclonal antibody that targets PILRA. Anti-PILRA Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PILRA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992288
-
|
|
Serpin
|
Inflammation/Immunology
|
|
Anti-PCI Antibody is a monoclonal antibody that targets PCI. Anti-PCI Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PCI Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991184
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992467
-
|
|
ADC Antibody
Claudin
|
Cancer
|
|
SOT102 Antibody is an IgG1 monoclonal antibody targeting CLDN18.2, and the antibody of ADC SOT102. SOT102 Antibody binds selectively to CLDN18.2, and promotes internalization. SOT102 Antibody can be used for the research of cancer [2].
|
-
(5)
- HY-P992013
-
|
|
CXCR
|
Others
|
|
Anti-CXCR3 Antibody (5H7) is a mouse monoclonal antibody produced using CXCR3 as the antigen. The recommended isotype control is human IgG1 kappa (HY-P99001).
|
-
(5)
- HY-P99330
-
|
Anti-Human VEGFA Recombinant antibody; RO5520985
|
VEGFR
Tie
|
Cancer
|
|
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
|
-
(5)
- HY-P990770
-
-
(5)
- HY-P990761
-
-
(5)
- HY-P990700
-
|
RO-7247669; RG-6139
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990694
-
|
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990701
-
|
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991195
-
|
SIM1811-03
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
(5)
- HY-P99893
-
|
AMG-570
|
CD28
TNF Receptor
|
Inflammation/Immunology
|
|
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases .
|
-
(5)
- HY-P99745
-
-
(5)
- HY-P991643
-
-
(5)
- HY-P99658
-
|
PRX-003
|
Inhibitory Antibodies
|
Cancer
|
|
Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent .
|
-
(5)
- HY-P99865
-
|
AK-119
|
CD73
|
Others
|
|
Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells .
|
-
(5)
- HY-P991470
-
|
Neuradiab antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-Tenascin C Antibody (Neuradiab antibody) is a human monoclonal antibody (mAb) targeting Tenascin C. Anti-Tenascin C Antibody can be used in Glioblastoma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991041
-
|
Anti-SEZ6 antibody (SC17); ABBV-011 antibody; ABBV-706 antibody
|
ADC Antibody
|
Cancer
|
|
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99971
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P990756
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
(5)
- HY-P990777
-
-
(5)
- HY-P990751
-
-
(5)
- HY-P991341
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
FF-21101 is a human IgG1 monoclonal antibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992123
-
|
AZD-5148
|
Bacterial
|
Infection
|
|
Ombetoxabart is a humanized IgG1-κ monoclonal antibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .
|
-
(5)
- HY-P990072
-
|
LZM-009
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
-
(5)
- HY-P990711
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
(5)
- HY-P99363
-
|
Anti-ICOS/CD278 Reference antibody (feladilimab); GSK3359609
|
Transmembrane Glycoprotein
|
Cancer
|
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonal antibody. Feladilimab can be used for the research of cancer .
|
-
(5)
- HY-P991072
-
|
MAPP-66
|
HIV
HSV
|
Infection
|
|
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990995A
-
|
7G6 antibody; 7G6-IgG2a
|
Tau Protein
|
Neurological Disease
|
|
Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonal antibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease .
|
-
(5)
- HY-P9904
-
|
MPDL3280A; RG-7446; RO-5541267
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
(5)
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
-
(5)
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
|
-
(5)
- HY-P992148
-
|
ZL-1310 antibody
|
Notch
|
Cancer
|
|
Zocilurtatug is a human monoclonal antibody against DLL3. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992139
-
|
|
VEGFR
|
Others
|
|
Valancitug is a human monoclonal antibody targeting VEGFA. Its corresponding isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
(5)
- HY-P992194
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-BCAM Antibody is a monoclonal antibody that targets BCAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-BCAM Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992227
-
|
|
Lipase
|
Inflammation/Immunology
|
|
Anti-Endothelial Lipase Antibody is a monoclonal antibody targeting endothelial lipase. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Endothelial Lipase Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992228
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-Fibronectin III Antibody is a monoclonal antibody targeting Fibronectin III. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Fibronectin III Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
(5)
- HY-P992293
-
|
|
RAR/RXR
|
Inflammation/Immunology
|
|
Anti-PRAME Antibody is a monoclonal antibody that targets the melanoma antigen preferentially/PRAME. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRAME Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992308
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-TrkC Antibody is a monoclonal antibody targeting TrkC/NTRK3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TrkC Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
(5)
- HY-P992192
-
|
|
GDNF Receptor
|
Inflammation/Immunology
|
|
Anti-Artemin Antibody is a monoclonal antibody that targets artemin. It can be used in ELISA, FACS, and functional assays. For isotype controls of anti-artemin antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P991391
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
|
-
(5)
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
|
|
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .
|
-
(5)
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
-
(5)
- HY-P991608
-
|
7F11C7
|
Mucin
|
Cancer
|
|
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
|
-
(5)
- HY-P991304
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
IO-106 is a human IgG1 monoclonal antibody (mAb) targeting LAIR1/CD305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992103
-
|
BNT326/YL202 antibody
|
ADC Payload
|
Cancer
|
|
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against HER3. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .
|
-
(5)
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
-
(5)
- HY-P992196
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-Canine CD28 Antibody (1C6) is a mouse-derived monoclonal antibody that targets canine CD28, which isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P990027
-
|
IMGC-936 antibody; MGA021
|
ADC Antibody
MMP
|
Cancer
|
|
Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
|
-
(5)
- HY-P990865
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-CD28 Antibody (9.3) is an anti-human CD28 IgG2a monoclonal antibody. Anti-CD28 Antibody (9.3) can activate T cells. Anti-CD28 Antibody (9.3) can be used for research on immunology. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
(5)
- HY-P99037
-
|
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
-
(5)
- HY-P992096
-
|
R-1549; HMFG1; Theragyn
|
Mucin
|
Cancer
|
|
Pemtumomab Antibody (R-1549) is an anti-MUC1 monoclonal antibody. Pemtumomab Antibody is applicable to research related to breast cancer and other cancers. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P99054
-
|
SAR-408377; PF-08046050 antibody; SAR445953 antibody
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .
|
-
(5)
- HY-P991645
-
|
MDX-1203 antibody; BMS-936561 antibody
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
MDX-1115 is a humanized IgG1 monoclonal antibody targeting CD70. MDX-1115 can be used for synthesis of ADC BMS-936561 .
|
-
(5)
- HY-P99743
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Mitumomab is an anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-cell lung carcinoma .
|
-
(5)
- HY-P99603
-
|
SEA-CD40
|
Inhibitory Antibodies
|
Cancer
|
|
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .
|
-
(5)
- HY-P99022
-
|
R-04909832; RG-1450
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
(5)
- HY-P990752
-
|
REGN-5678
|
CD28
|
Inflammation/Immunology
|
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992131
-
|
|
Mucin
|
Cancer
|
|
Sacomitatug is a humanized IgG1-κ monoclonal antibody targeting mucin 1 (MUC1). Sacomitatug exerts anti-tumor effects by blocking MUC1-mediated tumor proliferation signals and activating immune effectors .
|
-
(5)
- HY-P991333
-
-
(5)
- HY-P991183
-
|
|
CD28
CD38
CD3
|
Cancer
|
|
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
|
-
(5)
- HY-P991963
-
|
|
ERK
|
Others
|
|
Anti-Big-ET-1 Antibody is a humanized monoclonal antibody targeting Big-ET-1. Recommended Isotype Control: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992231
-
|
|
TAM Receptor
|
Inflammation/Immunology
|
|
Anti-GAS6 Antibody (KM5321) is a humanized anti-GAS6 monoclonal antibody. Its isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P99326
-
|
Anti-Human CD20 Recombinant antibody; V10XA53
|
CD20
|
Cancer
|
|
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
|
-
(5)
- HY-P99332
-
|
Anti-Human CD3E Recombinant antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
(5)
- HY-P992277
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-NKp46 Antibody is a monoclonal antibody targeting NKp46. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NKp46 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P992250
-
|
|
Kallikrein
|
Inflammation/Immunology
|
|
Anti-KLK7 Antibody is a monoclonal antibody targeting KLK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-KLK7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992217
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CDH19 Antibody is a monoclonal antibody that targets CDH19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CDH19 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992185
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-ADAM17 Antibody is a monoclonal antibody targeting ADAM17. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADAM17 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992297
-
|
|
E1/E2/E3 Enzyme
|
Inflammation/Immunology
|
|
Anti-RNF43 Antibody is a monoclonal antibody targeting RNF43. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RNF43 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992279
-
|
|
Notch
|
Inflammation/Immunology
|
|
Anti-Notch4 Antibody is a monoclonal antibody targeting Notch4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch4 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
(5)
- HY-P992186
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-ADMAST4 Antibody is a monoclonal antibody targeting ADMAST4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ADMAST4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992300
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-RSPO2 Antibody is a monoclonal antibody that targets RSPO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-RSPO2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992216
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD99 Antibody is a monoclonal antibody that targets CD99. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD99 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992187
-
|
|
PDI
|
Inflammation/Immunology
|
|
Anti-AGR2 Antibody is a monoclonal antibody that targets AGR2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-AGR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992307
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-TIMP-1 Antibody is a monoclonal antibody that targets TIMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TIMP-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992214
-
|
|
SHP1
|
Inflammation/Immunology
|
|
Anti-CD84 Antibody is a monoclonal antibody that targets CD84. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD84 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992251
-
-
(5)
- HY-P992197
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCL21 Antibody is a monoclonal antibody targeting CCL21. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL21 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992189
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-APCDD1 Antibody is a monoclonal antibody that targets APCDD1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-APCDD1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992255
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-LAIR1 Antibody is a monoclonal antibody that targets LAIR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LAIR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992305
-
|
|
STAT
|
Inflammation/Immunology
|
|
Anti-STAT3 Antibody is a monoclonal antibody that targets STAT3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-STAT3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992299
-
|
|
Slit Proteins
|
Inflammation/Immunology
|
|
Anti-Robo4 Antibody is a monoclonal antibody targeting Robo4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Robo4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992199
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCR9 Antibody is a monoclonal antibody targeting CCR9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCR9 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992309
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-TSPAN33 Antibody is a monoclonal antibody targeting TSPAN33. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TSPAN33 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992229
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-FZD5 Antibody is a monoclonal antibody targeting FZD5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-FZD5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992226
-
|
|
Orphan GPCR
|
Inflammation/Immunology
|
|
Anti-EMR2 Antibody is a monoclonal antibody targeting ADGRE2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-EMR2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992191
-
|
|
Apolipoprotein
|
Inflammation/Immunology
|
|
Anti-ApoL1 Antibody is a monoclonal antibody that targets ApoL1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ApoL1 Antibody, please refer to Rabbit IgG1 kappa, Isotype Control (HY-P99980).
|
-
(5)
- HY-P992269
-
|
|
Monocarboxylate Transporter
|
Inflammation/Immunology
|
|
Anti-MSR1 Antibody is a monoclonal antibody that targets MSR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MSR1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992222
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCL13 Antibody is a monoclonal antibody targeting CXCL13. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CXCL13 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992263
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-LRP5 Antibody is a monoclonal antibody that targets LRP5. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP5 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992287
-
|
|
Protein Arginine Deiminase
|
Inflammation/Immunology
|
|
Anti-PAD4 Antibody is a monoclonal antibody that targets PAD4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PAD4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992278
-
|
|
Notch
|
Inflammation/Immunology
|
|
Anti-Notch2 Antibody is a monoclonal antibody targeting Notch2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
-
(5)
- HY-P99357
-
|
REGN1193; Anti-GCGR Reference antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
-
(5)
- HY-P99494
-
|
TRC105; DE-122
|
TGF-beta/Smad
|
Cancer
|
|
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
|
-
(5)
- HY-P99195
-
|
REGN-475; SAR-164877
|
Trk Receptor
|
Inflammation/Immunology
|
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
-
(5)
- HY-P991179
-
|
|
TNF Receptor
|
Cancer
|
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
-
(5)
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
-
(5)
- HY-P990745
-
|
HIB210; MOR044254; MOR210; TJ-210; TJ-210001; WBP2191
|
Complement System
|
Inflammation/Immunology
|
|
Izastobart is an anti-C5AR1 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
(5)
- HY-P992375
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HuMax-IL15 is a human IgG1 monoclonal antibody against IL-15. HuMax-IL15 is applicable to the research of rheumatoid arthritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P990691
-
-
(5)
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990037
-
|
GEN3014
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .
|
-
(5)
- HY-P99909
-
|
PF-06863135; RN-613
|
TNF Receptor
|
Inflammation/Immunology
|
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
(5)
- HY-P990692
-
|
JNJ-70218902; JNJ-902
|
CD3
|
Inflammation/Immunology
|
|
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P990139
-
|
|
CD20
|
Inflammation/Immunology
|
|
Anti-Mouse CD20 Antibody (AISB12) is an anti-mouse CD20 IgG2a monoclonal antibody. Anti-Mouse CD20 Antibody (AISB12) can deplete B cells. Anti-Mouse CD20 Antibody (AISB12) can be used for research on immunology .
|
-
(5)
- HY-P99328
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
-
(5)
- HY-P99278
-
|
MT 201; Anti-Human EPCAM Recombinant antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .
|
-
(5)
- HY-P992295
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Protein S Antibody is a monoclonal antibody targeting Protein S. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Protein S Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992292
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Plexin A1 Antibody is a monoclonal antibody targeting Plexin A1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Plexin A1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992261
-
|
|
Lipocalin Family
|
Inflammation/Immunology
|
|
Anti-Lipocalin-2 Antibody is a monoclonal antibody targeting Lipocalin-2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Lipocalin-2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992248
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-32 Antibody is a monoclonal antibody that targets IL-32. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-32 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992240
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-19 Antibody is a monoclonal antibody that targets IL-19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-19 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P992245
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-26 Antibody is a monoclonal antibody that targets IL-26. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-26 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992218
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CHRDL-1 Antibody is a monoclonal antibody that targets CHRDL-1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CHRDL-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992243
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-24 Antibody is a monoclonal antibody that targets IL-24. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-24 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992267
-
|
|
MMP
|
Inflammation/Immunology
|
|
Anti-MMP-16 Antibody is a monoclonal antibody targeting MMP-16. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MMP-16 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99791
-
|
SYNT001; ALXN1830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity .
|
-
(5)
- HY-P990803
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonal antibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
(5)
- HY-P992213
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD79 Antibody is a monoclonal antibody that targets CD79. Anti-CD79 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD79 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992274
-
|
|
Transglutaminase
|
Inflammation/Immunology
|
|
Anti-NGLY1 Antibody is a monoclonal antibody that targets NGLY1. Anti-NGLY1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGLY1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990245
-
|
|
FAP
|
Cancer
|
|
Anti-Mouse FAP Antibody (73.3) is an anti-mouse FAP IgG1 monoclonal antibody. Anti-Mouse FAP Antibody (73.3) can be used to accurately detect the expression and localization of FAP protein in mice. Anti-Mouse FAP Antibody (73.3) can be used for research on cancer .
|
-
(5)
- HY-P992265
-
|
|
Monocarboxylate Transporter
|
Inflammation/Immunology
|
|
Anti-MCT1 Antibody is a monoclonal antibody that targets MCT1. Anti-MCT1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MCT1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992204
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD180 Antibody is a monoclonal antibody that targets CD180. Anti-CD180 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD180 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992268
-
|
|
MEK
|
Inflammation/Immunology
|
|
Anti-MP1 Antibody is a monoclonal antibody that targets MP1. Anti-MP1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-MP1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991305
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
|
-
(5)
- HY-P991314
-
|
|
MDM-2/p53
|
Cancer
|
|
NMC-001 is a human IgG1 monoclonal antibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99322
-
|
LFG316; Anti-Human C5 Recombinant antibody
|
Complement System
|
Inflammation/Immunology
|
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
-
(5)
- HY-P99995
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Human IgG1 (K214R) kappa, Isotype Control is a human IgG1 kappa monoclonal antibody mutant with a lysine-to-arginine substitution at position 214. Human IgG1 (K214R) kappa, Isotype Control is mainly used as an isotype control in experiments such as immunoprecipitation. Human IgG1 (K214R) kappa, Isotype Control binds to proteins non-specifically, thereby helping researchers verify the interactions of specific antibodies and ensure the accuracy of experimental results .
|
-
(5)
- HY-P9905
-
|
C225; IMC-C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
(5)
- HY-P99571
-
|
INH-H 2002
|
Inhibitory Antibodies
|
Infection
|
|
Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections .
|
-
(5)
- HY-P99537
-
|
PBP1510
|
Inhibitory Antibodies
|
Cancer
|
|
Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research .
|
-
(5)
- HY-P991681
-
|
ASP-2138
|
Claudin
CD3
|
Cancer
|
|
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
|
-
(5)
- HY-P991546
-
|
|
CD20
|
Cancer
|
|
MEDI-552 is a human IgG monoclonal antibody targeting CD20/membrane-spanning 4-domains subfamily A member 1 (MS4A1) .
|
-
(5)
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
-
(5)
- HY-P99831
-
|
GB-221
|
EGFR
|
Others
Cancer
|
|
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
|
-
(5)
- HY-P991903
-
|
|
CD20
|
Cancer
|
|
PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
|
-
(5)
- HY-P99465
-
-
(5)
- HY-P990162
-
|
AB1-2
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33) is an anti-mouse T15 VH and T15 VL regions of IgM IgG1 monoclonal antibody. Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33) is used in studies of the MHC class I heavy chain FcRn heterodimers and their interaction with IgG .
|
-
(5)
- HY-P992252
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-Kremen2 Antibody is a monoclonal antibody that targets Kremen2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Kremen2 Antibody, please refer to Human IgG1 (N297A) kappa, Isotype Control (HY-P99994).
|
-
(5)
- HY-P992207
-
|
|
SHP1
|
Inflammation/Immunology
|
|
Anti-CD300A Antibody is a monoclonal antibody targeting CD300A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300A Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P992210
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD326 Antibody (17-1A) is a human monoclonal antibody targeting CD326. Anti-CD326 Antibody (17-1A) can be used in cancer research. The recommended isotype control is Mouse IgG1 kappa (HY-P99977).
|
-
(5)
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992125
-
|
HFB-200603
|
CD28
|
Cancer
|
|
Radanstobart (HFB-200603) is a humanized monoclonal antibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991460
-
|
|
TNF Receptor
|
Cancer
|
|
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992412
-
|
|
Claudin
|
Cancer
|
|
MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P992198
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCL28 Antibody is a monoclonal antibody targeting CCL28. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CCL28 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P99307
-
|
AMG-203; Anti-Human CSF2 Recombinant antibody
|
c-Fms
|
Inflammation/Immunology
|
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
-
(5)
- HY-P991670
-
|
AVTX-009
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abdakibart is a humanized IgG4 monoclonal antibody inhibitor targeting IL-1β. Abdakibart can be used for inflammatory disease like type 2 diabetes research .
|
-
(5)
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
-
(5)
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
-
(5)
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
-
(5)
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
-
(5)
- HY-P99262
-
|
BAX69; Anti-Human MIF Recombinant antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
(5)
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .
|
-
(5)
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
-
(5)
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
-
(5)
- HY-P9925
-
|
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
-
(5)
- HY-P990036
-
|
PF-06823859
|
IFNAR
|
Inflammation/Immunology
|
|
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
|
-
(5)
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
-
(5)
- HY-P992225
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-DR3 Antibody is a monoclonal antibody that targets DR3. Anti-DR3 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DR3 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P99271
-
|
Anti-Human F3 Recombinant antibody
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
|
-
(5)
- HY-P992224
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-DKK2 Antibody is a monoclonal antibody that targets DKK2. Anti-DKK2 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-DKK2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P99009
-
|
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
-
(5)
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
(5)
- HY-P99368
-
|
MCS110
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
-
(5)
- HY-P991484
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990007
-
|
PRA023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
|
-
(5)
- HY-P991450
-
|
ADI-15742; MBP-134 AF
|
Filovirus
|
Infection
|
|
ADI-15878 is a human IgG monoclonal antibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99206A
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Naxitamab (Hu3F8) (Mouse IgG1) is a mouse-derived IgG1 monoclonal antibody targeting the diazoglycoside GD2 (hu3F8). Naxitamab can be used in the research of neuroblastoma, osteosarcoma, and other GD2-positive cancers .
|
-
(5)
- HY-P991489
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ENx-108A is a human IgG4 monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991483
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990086
-
|
RG-6292; RO-7296682
|
Interleukin Related
|
Cancer
|
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity .
|
-
(5)
- HY-P991942
-
|
BAY3375968; TPP-23411
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
|
-
(5)
- HY-P992249
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-34 Antibody is a monoclonal antibody that targets IL-34. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-34 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992128
-
|
|
EGFR
|
Others
|
|
Rinumafusp alfa is a human monoclonal antibody targeting ERBB3/HER3. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99181
-
-
(5)
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
(5)
- HY-P99670
-
-
(5)
- HY-P99695
-
|
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
-
(5)
- HY-P99423
-
|
ADG 20
|
SARS-CoV
|
Infection
|
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
-
(5)
- HY-P99955
-
-
(5)
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
-
(5)
- HY-P991434
-
|
|
Integrin
|
Inflammation/Immunology
|
|
SAN-300 is a human IgG1 monoclonal antibody (mAb) targeting ITGA1/VLA-1. SAN-300 can be used in Rheumatoid arthritis research .
|
-
(5)
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
-
(5)
- HY-P991721
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
|
-
(5)
- HY-P99053
-
-
(5)
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
-
(5)
- HY-P99889
-
|
BRII-198
|
SARS-CoV
|
Infection
|
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
(5)
- HY-P99691
-
-
(5)
- HY-P9S0008
-
|
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
|
-
(5)
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
-
(5)
- HY-P99366A
-
|
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
-
(5)
- HY-P991300
-
|
|
LAG-3
|
Cancer
|
|
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99403
-
|
GSK249320
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Refanezumab (GSK249320) is a brain-penetrant IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab has the potential for the enhancement of recovery of function poststroke .
|
-
(5)
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
-
(5)
- HY-P992258
-
|
|
RXFP Receptor
|
Inflammation/Immunology
|
|
Anti-LGR7 Antibody is a monoclonal antibody targeting LGR7/RXFP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGR7 Antibody, please refer to Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
(5)
- HY-P992310
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-UPK-1B Antibody is a monoclonal antibody targeting UPK1B. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-UPK-1B Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992208
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD300C Antibody is a monoclonal antibody targeting CD300C. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300C Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992257
-
|
|
Galectin
|
Inflammation/Immunology
|
|
Anti-LGALS3BP Antibody is a monoclonal antibody targeting LGALS3BP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LGALS3BP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992306
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-TEM8 Antibody is a monoclonal antibody targeting TEM8/ANTXR1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TEM8 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991110
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonal antibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
|
-
(5)
- HY-P992276
-
-
(5)
- HY-P992302
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-SEMA3A Antibody is a monoclonal antibody targeting SEMA3A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-SEMA3A Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992273
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Anti-NGF2 Antibody is a monoclonal antibody targeting NGF2/NT-3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGF2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P992195
-
|
|
FGFR
|
Inflammation/Immunology
|
|
Anti-Beta Klotho Antibody is a monoclonal antibody targeting *Beta Klotho*. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Beta Klotho Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
(5)
- HY-P992051
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990797
-
|
|
IFNAR
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IFN gamma Antibody (R4-6A2) is an anti-mouse IFN gamma IgG1 monoclonal antibody. Anti-Mouse IFN gamma Antibody (R4-6A2) can increase the total serum IgG level. Anti-Mouse IFN gamma Antibody (R4-6A2) can be used for researches on immunology and infection conditions such as nymphs infection. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
(5)
- HY-P990818
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991374
-
|
|
Tau Protein
|
Neurological Disease
|
|
PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991442
-
|
TAK-920
|
TREM receptor
|
Neurological Disease
|
|
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99900
-
|
MSL-109
|
CMV
|
Infection
|
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
-
(5)
- HY-P991399
-
-
(5)
- HY-P99411
-
|
SHP647
|
Integrin
|
Inflammation/Immunology
|
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
|
-
(5)
- HY-P99362
-
|
Anti-MUC5AC Reference antibody (ensituximab); NEO-102
|
Mucin
|
Cancer
|
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
|
-
(5)
- HY-P99700
-
|
IBI-188
|
Inhibitory Antibodies
|
Cancer
|
|
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
|
-
(5)
- HY-P99438
-
|
KIND-030
|
Inhibitory Antibodies
|
Infection
|
|
Anivovetmab (KIND-030) is an anti-VP2 protein (canine parvovirus major capsid protein) monoclonal antibody (IgG2 isotype). Anivovetmab has the potential for studying canine parvovirus infection .
|
-
(5)
- HY-P992402
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MAI1738 is a human monoclonal antibody targeting PODXL. MAI1738 can be used for cancer-related research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99462
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
-
(5)
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
(5)
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
-
(5)
- HY-P99040
-
|
JNJ-61610588; CI-8993; VSTB112
|
VISTA
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
|
-
(5)
- HY-P992486
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
XKH001 is a recombinant humanized IgG1 monoclonal antibody targeting IL-25. XKH001 has low immunogenicity. XKH001 can be used for the research of type 2 inflammatory diseases .
|
-
(5)
- HY-P992235
-
-
(5)
- HY-P992221
-
|
|
Gap Junction Protein
|
Inflammation/Immunology
|
|
Anti-CLDN9 Antibody is a monoclonal antibody targeting CLDN9. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CLDN9 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
(5)
- HY-P992188
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Anti-ALK7 Antibody is a monoclonal antibody that targets ALK7. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ALK7 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
(5)
- HY-P992289
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Anti-PD-L2 Antibody is a monoclonal antibody targeting PD-L2/CD273. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PD-L2 Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P992246
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-27RA Antibody is a monoclonal antibody that targets IL-27RA. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-27RA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992264
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-LRP6 Antibody is a monoclonal antibody that targets LRP6. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LRP6 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
(5)
- HY-P992236
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-17F Antibody is a monoclonal antibody that targets IL-17F. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17F Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992253
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-L1-CAM Antibody is a monoclonal antibody that targets L1-CAM. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-L1-CAM Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991723
-
|
CX-2051 antibody
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .
|
-
(5)
- HY-P992242
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-23R Antibody is a monoclonal antibody that targets IL-23R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-23R Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992298
-
|
|
Slit Proteins
|
Inflammation/Immunology
|
|
Anti-ROBO2 Antibody is a monoclonal antibody targeting ROBO2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ROBO2 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
(5)
- HY-P992193
-
|
|
APC
|
Inflammation/Immunology
|
|
Anti-B7-H7 Antibody is a monoclonal antibody targeting HHLA2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-B7-H7 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992237
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-17RB Antibody is a monoclonal antibody targeting IL-17RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-17RB Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992205
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD226 Antibody is a monoclonal antibody targeting CD226. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD226 Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
(5)
- HY-P990150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse TSLP Antibody (28F12) is an anti-mouse TSLP IgG2a monoclonal antibody. Anti-Mouse TSLP Antibody (28F12) weakens skin inflammation and allergic reactions by reducing Treg cells and lymph node cells. Anti-Mouse TSLP Antibody (28F12) can be used for research on allergic conditions .
|
-
(5)
- HY-P990302
-
|
|
nAChR
|
Neurological Disease
|
|
Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonal antibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models .
|
-
(5)
- HY-P991404
-
|
|
TNF Receptor
|
Cancer
|
|
AMG-228 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. AMG-228 can be used in advanced solid tumors research .
|
-
(5)
- HY-P99591
-
|
AS1402; huHMFG-1; Epitumomab
|
Mucin
|
Cancer
|
|
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
|
-
(5)
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
-
(5)
- HY-P991433
-
|
|
TNF Receptor
|
Cancer
|
|
BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
|
-
(5)
- HY-P99949
-
|
OMP-313M32
|
Inhibitory Antibodies
|
Cancer
|
|
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .
|
-
(5)
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
-
(5)
- HY-P990766
-
|
AZD3152
|
SARS-CoV
|
Infection
|
|
Sipavibart (AZD3152) is a human IgG1 λ2 monoclonal antibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
(5)
- HY-P99729
-
|
GSK 3772847; CNTO-7160
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma .
|
-
(5)
- HY-P991495
-
|
|
RSV
|
Infection
|
|
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991301
-
|
|
LAG-3
|
Cancer
|
|
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992132
-
|
STAR-0310
|
TNF Receptor
|
Inflammation/Immunology
|
|
Solaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4/OX40L. Solaprubart regulates immune homeostasis by blocking the OX40L-OX40 signaling pathway and can be used for the research of autoimmune diseases such as atopic dermatitis .
|
-
(5)
- HY-P990591
-
|
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-1070806 (Aletekitug) is a humanized IgG1/κ monoclonal antibody targeting IL-18. GSK-1070806 neutralizes IL-18 activity.GSK-1070806 can be used for the research of inflammation. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991279
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonal antibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
|
-
(5)
- HY-P99382A
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Vopratelimab (Mouse IgG2a) is a agonist monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy .
|
-
(5)
- HY-P991840
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-CD68 Antibody (KP1) is a anti-CD68 monoclonal antibody (mAb). CD68 is present in various cell types, including monocytes/macrophages and fibroblasts. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991523
-
|
|
Apoptosis
|
Cancer
|
|
BI-836826 is a IgG1 chimerized and Fc-engineered anti-CD37 monoclonal antibody. BI 836826 displays both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic activities. BI-836826 can be used for the study of chronic lymphocytic leukemia .
|
-
(5)
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
(5)
- HY-P990285
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Mouse CD200 Antibody (OX-90) is an anti-mouse CD200 IgG2a monoclonal antibody. Anti-Mouse CD200 Antibody (OX-90) can reduce immune cell infiltration and T cell function by blocking CD200. Anti-Mouse CD200 Antibody (OX-90) can be used for research on immunology .
|
-
(5)
- HY-P99271A
-
|
Anti-Human F3 Recombinant antibody (powder)
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
|
-
(5)
- HY-P99677
-
|
ZTS-00075623
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonal antibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis .
|
-
(5)
- HY-P99514
-
|
AGEN1884
|
CTLA-4
|
Cancer
|
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
-
(5)
- HY-P99485
-
|
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
-
(5)
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
-
(5)
- HY-P991711
-
|
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Povovetug is a humanized IgG1κ chimeric monoclonal antibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
|
-
(5)
- HY-P991334
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
INCAGN1949 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. INCAGN1949 selectively deplete intratumoral regulatory T cells .
|
-
(5)
- HY-P992219
-
|
|
Claudin
|
Inflammation/Immunology
|
|
Anti-Claudin 1 Antibody is a monoclonal antibody targeting CLDN1/CLD1/SEMP1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Claudin 1 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992239
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-18Rα Antibody is a monoclonal antibody targeting IL-18Ra. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18Rα Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991431
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD133/PROM1 Antibody (CMab-43) is a human IgG2a monoclonal antibody (mAb) targeting PROM1/CD133. Anti-CD133/PROM1 Antibody (CMab-43) can be used in colon cancer research .
|
-
(5)
- HY-P992260
-
|
|
LILRB
|
Inflammation/Immunology
|
|
Anti-LILRB3 Antibody is a monoclonal antibody targeting LILRB3/ILT5/CD85a. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992259
-
|
|
LILRB
|
Inflammation/Immunology
|
|
Anti-LILRB1 Antibody is a monoclonal antibody targeting LILRB1/CD85j/ILT2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992286
-
|
|
P2X Receptor
|
Inflammation/Immunology
|
|
Anti-P2XR4 Antibody is a monoclonal antibody targeting P2XR4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-P2XR4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992303
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Siglec-10/CD24 Antibody is a monoclonal antibody targeting Siglec-10. It can be used in ELISA, FACS, and functional assays. Isotype controls for Anti-Siglec-10/CD24 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990868
-
|
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonal antibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982) .
|
-
(5)
- HY-P990870
-
|
|
CD19
IFNAR
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991869
-
|
AQmabAM; rAb-53
|
Aquaporin
|
Neurological Disease
|
|
Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
|
-
(5)
- HY-P990110
-
|
Mab158
|
Amyloid-β
|
Neurological Disease
|
|
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
|
-
(5)
- HY-P99289
-
|
antibody hLL 2; AMG-412
|
CD22
|
Inflammation/Immunology
Cancer
|
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
|
-
(5)
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human anti-IL31 IgG1-κ monoclonal antibody. BMS-981164 effectively inhibits the IL-31 signaling pathway. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 is applicable to research related to atopic dermatitis .
|
-
(5)
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991482
-
|
|
Influenza Virus
|
Infection
|
|
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992400
-
|
|
Tau Protein
|
Neurological Disease
|
|
Lu AF87908 is an IgG1 monoclonal antibody targeting the p-Ser396/404 epitope of tau protein, which mainly binds to the pSer396 region. Lu AF87908 can be used in the research of Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
-
(5)
- HY-P99353
-
|
Anti-ACVRL1 / ALK-1 Reference antibody (ascrinvacumab); PF-03446962; GT-90001C
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
-
(5)
- HY-P991690
-
|
|
RSV
|
Infection
|
|
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
|
-
(5)
- HY-P991471
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
GB-0895 is a human monoclonal antibody (mAb) targeting TSLP. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99185
-
|
AAB-001
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
-
(5)
- HY-P991688
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
|
-
(5)
- HY-P99183
-
|
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
|
-
(5)
- HY-P991717
-
|
AZD-8630
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
|
-
(5)
- HY-P992373
-
|
|
Mucin
|
Cancer
|
|
huCC49 is a human monoclonal antibody targeting TAG-72. huCC49 can be used in cancer-related research. The recommended isotype control is human IgG1 kappa, with the isotype control (HY-P99001) .
|
-
(5)
- HY-P992182
-
|
|
Interleukin Related
IFNAR
CD28
|
Inflammation/Immunology
|
|
ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].
|
-
(5)
- HY-P990241
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR (D265A) Antibody (DTA-1) is an anti-mouse GITR IgG1 monoclonal antibody. Anti-Mouse GITR (D265A) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (D265A) Antibody (DTA-1) contains the D265A mutation region. Anti-Mouse GITR (D265A) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (D265A) Antibody (DTA-1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P990240
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is an anti-mouse GITR IgG2a monoclonal antibody. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is a chimeric antibody of the original DTA-1 antibody (HY-P990124). Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) contains the LALA-PG mutation region. Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) can be used for research on cancer and allergic conditions. The recommed isotype control of Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
(5)
- HY-P99128
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8 + T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology .
|
-
(5)
- HY-P990159
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCRβ Antibody (HB218) is an anti-mouse TCRβ IgG2b monoclonal antibody. Anti-Mouse TCRβ Antibody (HB218) can deplete TCRβ + T cells. Anti-Mouse TCRβ Antibody (HB218) can be used for research on inflammation conditions and cancer such as spontaneous dermatitis and squamous cell carcinoma (SCC) .
|
-
(5)
- HY-P992238
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-18RAP Antibody is a monoclonal antibody targeting IL-18RAP/IL-18RB. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-18RAP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992280
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-NRP2 Antibody is a monoclonal antibody targeting NRP2/VEGF165R2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NRP2 Antibody, please refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P992133
-
|
SYS6002 antibody; CRB-701 antibody
|
ADC Antibody
Nectin-4
|
Cancer
|
|
Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991454
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-LGR5/GPR49 Antibody (18G7H6A3) is a human monoclonal antibody (mAb) targeting LGR5/GPR49. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991453
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonal antibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
(5)
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
-
(5)
- HY-P99730
-
|
TAK-079
|
CD38
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
|
-
(5)
- HY-P991892
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 is a humanized anti-CD4 monoclonal IgG1 antibody. IT1208 depletes CD4 + T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research .
|
-
(5)
- HY-P99945
-
-
(5)
- HY-P9942
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Sulesomab (IMMU-MN3) is a murine monoclonal antibody fragment of the IgG1 class that binds to Normal Cross-Reactive Antigen-90 present on leukocytes. Sulesomab is cleared into infection nonspecifically through increased capillary membrane permeability .
|
-
(5)
- HY-P99041
-
|
ABX-EGF
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
-
(5)
- HY-P991554
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
|
-
(5)
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
-
(5)
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
-
(5)
- HY-P9801
-
|
SARS-CoV-2 (2019-nCoV) Spike RBD antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
(5)
- HY-P990838
-
|
|
Interleukin Related
IFNAR
|
Inflammation/Immunology
|
|
Anti-IL-12 p70 Antibody (20C2) is an anti-human IL-12 p70 IgG1 monoclonal antibody. Anti-IL-12 p70 Antibody (20C2) can inhibit the production of IFN-γ. Anti-IL-12 p70 Antibody (20C2) can be used for research on inflammation conditions. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
(5)
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991292
-
|
|
ADC Antibody
|
Cancer
|
|
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991448
-
|
|
Glycoprotein VI
|
Cancer
|
|
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991112
-
|
|
Transmembrane Glycoprotein
|
Infection
|
|
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
|
-
(5)
- HY-P990146
-
|
|
Ras
|
Inflammation/Immunology
|
|
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is an anti-mouse/rat/human v-H-Ras IgG2a monoclonal antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) can be used as a control antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is often used for immunofluorescence and immunoprecipitation .
|
-
(5)
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .
|
-
(5)
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
-
(5)
- HY-P991421
-
|
|
VISTA
|
Cancer
|
|
W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
|
-
(5)
- HY-P992141
-
-
(5)
- HY-P99041B
-
|
ABX-EGF (powder)
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
|
-
(5)
- HY-P99513
-
|
CTB011
|
RABV
|
Infection
|
|
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
|
-
(5)
- HY-P99265
-
|
HGS-ETR1; Anti-Human TNFRSF10A Recombinant antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
|
-
(5)
- HY-P991730
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Kiatomab is a monoclonal antibody targeting the mouse cancer stem cell-specific antigen KIAA1114. Kiatomab has anti-tumor activity. The corresponding isotype control is Mouse IgG2b kappa, Isotype Control (HY-P99982) .
|
-
(5)
- HY-P991192
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
|
-
(5)
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
-
(5)
- HY-P99904
-
|
MEDI-507; TCD601
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
-
(5)
- HY-P991652
-
|
RG-7594
|
Integrin
|
Cancer
|
|
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
|
-
(5)
- HY-P991473
-
|
|
TNF Receptor
|
Cancer
|
|
hCBE-11 is a human monoclonal antibody (mAb) targeting TNFRSF3. hCBE-11 can be used in solid tumors research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P9807
-
|
SARS-CR3022; SARS-CoV-2 antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
-
(5)
- HY-P991507
-
|
Demupitamab
|
EGFR
|
Cancer
|
|
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
|
-
(5)
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
(5)
- HY-P9968
-
|
h-R3
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
(5)
- HY-P990869
-
|
|
CD1
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P990790
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonal antibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8 + T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
-
(5)
- HY-P9990
-
-
(5)
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
-
(5)
- HY-P99701
-
|
BMS-986004
|
TNF Receptor
|
Inflammation/Immunology
|
|
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
|
-
(5)
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
|
-
(5)
- HY-P991589
-
|
NOV-1105
|
c-Met/HGFR
|
Cancer
|
|
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
|
-
(5)
- HY-P991612
-
|
Sym024
|
CD73
|
Inflammation/Immunology
Cancer
|
|
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
|
-
(5)
- HY-P99283
-
|
NN 7415; mAb 2021; Anti-TFPI Recombinant antibody
|
Factor Xa
|
Others
|
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
|
-
(5)
- HY-P990006
-
|
TEV-48574; SAR-447189; TEV-574
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
-
(5)
- HY-P991311
-
|
|
LPL Receptor
Wnt
|
Cancer
|
|
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
(5)
- HY-P990679
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Rat IgG2a kappa, Isotype Control is a monoclonal antibody derived from rats, representing the immunoglobulin G2a (IgG2a) subclass with a kappa light chain. Rat IgG2a kappa, Isotype Control exhibits high efficiency in inducing K cell mediated cytotoxicity. Rat IgG2a kappa, Isotype Control is utilized in research investigating the roles of different immunoglobulin subclasses in tumor immunology. Rat IgG2a kappa, an isotype control, can be used as an isotype control for Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144), Anti-Mouse CD11a/LFA-1α Antibody (M17/4) (HY-P990801), and Anti-Mouse IL-2 Antibody (S4B6-1) (HY-P990796) .
|
-
(5)
- HY-P992241
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL-21R Antibody is a monoclonal antibody targeting IL-21R. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-21R Antibody, please refer to Human IgG1 (L234A/L235A) kappa, Isotype Control (HY-P991207).
|
-
(5)
- HY-P992346
-
|
|
CD47
|
Cancer
|
|
DS-1103a is a humanized IgG4 monoclonal antibody targeting SIRPa/CD172a. DS-1103a inhibits the interaction between SIRPα and CD47. DS-1103a enhances antibody-dependent cellular phagocytosis of cancer cells. DS-1103a can be used for the research of solid tumors. The recommended isotype control is: Human IgG4 (S228P) kappa, (HY-P99003) .
|
-
(5)
- HY-P991458
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P9965
-
|
HuLuc 63; PDL 063; BMS 901608
|
Transmembrane Glycoprotein
|
Cancer
|
|
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
|
-
(5)
- HY-P99313
-
|
Anti-Human IGHE Recombinant antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
(5)
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-108730
-
|
Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
|
-
(5)
- HY-P99194
-
|
REGN1500
|
ANGPTL
|
Cardiovascular Disease
Metabolic Disease
|
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
-
(5)
- HY-P99335
-
|
Anti-Human IL17A Recombinant antibody; SHR-1314
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .
|
-
(5)
- HY-P990179
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2AB6 Antibody (16A11) is an anti-mouse NKG2AB6 IgG2b monoclonal antibody. Anti-Mouse NKG2AB6 Antibody (16A11) reduces depletion of antigen-specific CD8 T cells. Anti-Mouse NKG2AB6 Antibody (16A11) can be used for research on cancer such as lung cancer and colon cancer .
|
-
(5)
- HY-P990119
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) is an anti-mouse Kappa Immunoglobulin Light Chain IgG1 monoclonal antibody. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can reduce the phosphorylation levels of Src and Syk in B cells and the antigen presentation ability of B cells. Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) can be used for research on immunology .
|
-
(5)
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
-
(5)
- HY-P992411
-
|
|
Amyloid-β
|
Neurological Disease
|
|
MEDI-8490 is a fully human monoclonal antibody targeting APP/Aβ. MEDI-8490 can be used in research related to neurodegenerative diseases. Recommended isotype control: Human IgG1 lambda1, Isotype Control (HY-P99992).
|
-
(5)
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
(5)
- HY-P99786
-
|
REGN3918
|
Complement System
|
Metabolic Disease
|
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
-
(5)
- HY-P99110
-
|
SHP643; DX-2930; X124-G01
|
Kallikrein
|
Inflammation/Immunology
|
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
-
(5)
- HY-P990145
-
|
|
VISTA
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF .
|
-
(5)
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
-
(5)
- HY-P990792
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 + T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
- HY-P990730
-
|
ARB202
|
CD3
Cadherin
|
Cancer
|
|
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .
|
-
(5)
- HY-P991393
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
ASP8374 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991445
-
|
|
SARS-CoV
|
Infection
|
|
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991493
-
|
|
RSV
|
Infection
|
|
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992063
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonal antibody that binds to CD8α on mouse CD8 + T cells. When used in combination with a non-depleting anti-CD4 antibody, Anti-Mouse CD8α Antibody (YTS 105.18) does not deplete CD8 + T cells, but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used for research on graft rejection. The recommended isotype control is Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
(5)
- HY-P99114
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
-
(5)
- HY-P991516
-
|
|
Factor VIII
|
Cardiovascular Disease
|
|
TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) .
|
-
(5)
- HY-P99036
-
|
|
Tie
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches .
|
-
(5)
- HY-P9915
-
|
Anti-Human CD38, Human antibody; HuMax-CD38; JNJ-54767414
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
(5)
- HY-P991186
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model .
|
-
(5)
- HY-P99351
-
|
Anti-MMP9 Reference antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
-
(5)
- HY-P991689
-
|
|
VEGFR
|
Cancer
|
|
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
|
-
(5)
- HY-P99327
-
|
BT-061
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
|
-
(5)
- HY-P99041A
-
|
|
EGFR
|
Cancer
|
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
-
(5)
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
-
(5)
- HY-P99376
-
|
OMS 721; Anti-MASP2 Reference antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
-
(5)
- HY-P991426
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
|
-
(5)
- HY-P9968A
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
(5)
- HY-P99263
-
|
Anti-Human selectin P Recombinant antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
(5)
- HY-P990109
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC50s of >1 μM and 0.2 nM for monomeric Aβ1-40 and fibrillar Aβ1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .
|
-
(5)
- HY-P99970
-
|
|
ADC Antibody
Sodium Phosphate Cotransporter
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992167
-
|
|
Claudin
|
Cancer
|
|
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .
|
-
(5)
- HY-P99490
-
|
hzVSF-v13
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
|
-
(5)
- HY-P99216
-
|
PF-04360365; RN 1219
|
Amyloid-β
|
Neurological Disease
|
|
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .
|
-
(5)
- HY-P99287
-
|
B-E8; Anti-IL-6 MAB B-E8
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
|
-
(5)
- HY-P99220
-
|
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
-
(5)
- HY-P9907A
-
|
Anti-Human HER2, Humanized antibody (anti-HER2)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
(5)
- HY-P99317
-
|
LY-2062430
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
|
-
(5)
- HY-P99336
-
|
BI-RR 0001; Anti-Human IL6 Recombinant antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
-
(5)
- HY-P990714
-
|
|
CD3
|
Inflammation/Immunology
|
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
-
(5)
- HY-P991496
-
|
|
RSV
|
Infection
|
|
IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
(5)
- HY-P990124
-
|
|
TNF Receptor
NF-κB
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682) .
|
-
(5)
- HY-P9929
-
|
BLA761046; MBL-CDB1; MDX-1388
|
Bacterial
|
Infection
|
|
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
|
-
(5)
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
(5)
- HY-P992399
-
|
|
TNF Receptor
NF-κB
|
Cancer
|
|
LBL-019 is a humanized IgG1 monoclonal antibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P990800
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse IL-4 Antibody (BVD6-24G2) is an anti-mouse IL-4 IgG1 monoclonal antibody. Anti-Mouse IL-4 Antibody (BVD6-24G2) can inhibit IL-4 signaling and promote Treg differentiation. Anti-Mouse IL-4 Antibody (BVD6-24G2) can be used for research on immunology. The recommend isotype control of Anti-Mouse IL-4 Antibody (BVD6-24G2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
|
-
(5)
- HY-P991465
-
|
|
TNF Receptor
|
Cancer
|
|
Anti-CD27 Antibody (M2177) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2177) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2177) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991466
-
|
|
TNF Receptor
|
Cancer
|
|
Anti-CD27 Antibody (M2191) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2191) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2191) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990207
-
|
|
Integrin
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is an anti-mouse/human Integrin β7 IgG2a monoclonal antibody. Anti-Mouse/Human Integrin β7 Antibody (FIB504) can reduce the residence of type 2 innate lymphoid cells (ILC2s). Anti-Mouse/Human Integrin β7 Antibody (FIB504) can be used for researches on inflammation conditions and cancer such as lupus nephritis and glioma .
|
-
(5)
- HY-P990181
-
|
|
Glutathione Peroxidase
STING
|
Inflammation/Immunology
|
|
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonal antibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) .
|
-
(5)
- HY-P990558
-
|
BMS-986148 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
BMS-986021 (BMS-986148 antibody) is a human monoclonal antibody expressed in CHO, targeting Mesothelin. BMS-986021 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986021, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P990051
-
|
AOC-1001 antibody; AOC-1044 antibody
|
Transferrin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Delpacibart is a humanized IgG1κ monoclonal antibody targeting the transferrin receptor TFRC. Delpacibart can be conjugated with the phosphorodiamidate morpholino oligonucleotide (PMO) Zotadirsen (HY-177972), which targets exon 44 of the dystrophin gene, to synthesize the antibody-oligonucleotide conjugate (AOC) Delpacibart zotadirsen (HY-177564). Delpacibart is suitable for use in Duchenne muscular dystrophy (DMD44) research .
|
-
(5)
- HY-P99964
-
|
AGS15C; Ha15-10ac12; Ha15-10ac12.1
|
Inhibitory Antibodies
|
Cancer
|
|
Sirtratumab (AGS15C; Ha15-10ac12; Ha15-10ac12.1) is a SLITRK6-specific humanized IgG2 monoclonal antibody, and serves as the parental antibody of the ADC ASG-15ME (HY-P99595). Sirtratumab is applicable for cancer research .
|
-
(5)
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
-
(5)
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
-
(5)
- HY-P99039
-
|
MEDI9447
|
CD73
|
Cancer
|
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
-
(5)
- HY-P991593
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
|
-
(5)
- HY-P99727
-
|
CTB012
|
RABV
|
Infection
|
|
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
|
-
(5)
- HY-P99541
-
|
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
-
(5)
- HY-P991345
-
|
AMP-514
|
PD-1/PD-L1
|
Cancer
|
|
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
|
-
(5)
- HY-P992215
-
|
|
LILRB
|
Inflammation/Immunology
|
|
Anti-CD85a/LILRB3 Antibody (7C5) is a human monoclonal antibody targeting LILRB3/ILT5/CD85a. Anti-CD85a/LILRB3 Antibody (7C5) can be used for research on inflammatory and immune diseases. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).
|
-
(5)
- HY-P992156
-
|
|
LAG-3
|
Cancer
|
|
Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonal antibody that specifically binds to human, mouse and bovine LAG-3. Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) can be used in the research of colon cancer, colorectal cancer and rectal cancer. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991196
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990015
-
|
VIR-3434
|
HBV
|
Infection
|
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
(5)
- HY-P990867
-
|
|
Insulin Receptor
Akt
|
Cancer
|
|
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is an anti-human CD220/Insulin Receptor IgG1 monoclonal antibody. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can block Akt overactivation caused by Trip13 deficiency. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can be used for research on cancer such as hepatocellular carcinoma (HCC). Anti-CD220/Insulin Receptor Antibody (IR 83-22) often used in western blotting. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P990855
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
(5)
- HY-P9915A
-
|
Anti-Human CD38, Human antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
(5)
- HY-P991237
-
|
HMBD-001
|
EGFR
|
Cancer
|
|
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
|
-
(5)
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
(5)
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
(5)
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
(5)
- HY-P99299
-
|
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
-
(5)
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
-
(5)
- HY-P992008
-
|
|
TGF-β Receptor
|
Cardiovascular Disease
|
|
PF-07868489 is a recombinant monoclonal antibody targeting GDF2/BMP-9. PF-07868489 can be used for the research of pulmonary arterial hypertension (PAH). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990031
-
|
M-6223
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
-
(5)
- HY-P99143
-
|
|
Neurokinin Receptor
NF-κB
STAT
|
Inflammation/Immunology
|
|
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
|
-
(5)
- HY-P990126
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
|
|
Anti-Rat CD8α Antibody (OX-8) is an anti-rat CD8α IgG1 monoclonal antibody. Anti-Rat CD8α Antibody (OX-8) can deplete CD8 + T cells. Anti-Rat CD8α Antibody (OX-8) can enhance airway remodeling. Anti-Rat CD8α Antibody (OX-8) can be used for researches on allergic conditions and infections such as RHV-rn1 virus infection and asthma .
|
-
(5)
- HY-P990243
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse FGL-1 Antibody (177R4) is an anti-mouse FGL-1 IgG2a monoclonal antibody. Anti-Mouse FGL-1 Antibody (177R4) can increase CD8 + T cell infiltration. Anti-Mouse FGL-1 Antibody (177R4) enhances the anti-tumor immune effect by blocking FGL1. Anti-Mouse FGL-1 Antibody (177R4) can be used for research on cancer such as lung cancer and breast cancer .
|
-
(5)
- HY-P990239
-
|
|
HSP
Akt
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonal antibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation .
|
-
(5)
- HY-P990140
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Rat β-2-Microglobulin Antibody (4C9) is an anti-rat β-2-Microglobulin IgG1 monoclonal antibody. Anti-Rat β-2-Microglobulin Antibody (4C9) reduces pJNK nuclear translocation and restore SMAD nuclear localization. Anti-Rat β-2-Microglobulin Antibody (4C9) is often used in immunoprecipitation experiments .
|
-
(5)
- HY-P990217
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived anti-mouse IL-23 p19 IgG1 monoclonal antibody. Anti-Mouse IL-23 p19 Antibody (G23-8) alleviates inflammation by restoring CLDN8 expression. Anti-Mouse IL-23 p19 Antibody (G23-8) can be used for research on inflammation conditions such as colitis and asthma .
|
-
(5)
- HY-P990174
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is an anti-mouse Pan-endothelial Cell Antigen/MECA-32 IgG2a monoclonal antibody. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) can label endothelial cells. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is often used for immunohistochemistry, delivery of siRNA and immunofluorescence .
|
-
(5)
- HY-P99149
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonal antibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for researches on inflammation conditions and cancer such as breast cancer .
|
-
(5)
- HY-P990572
-
DCBY02
1 Publications Verification
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
DCBY02 is a monoclonal antibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
|
-
(5)
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
|
-
(5)
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
-
(5)
- HY-P99050
-
|
BIVV009; IPN-009; TNT009
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
|
-
(5)
- HY-P991446
-
|
|
Influenza Virus
|
Infection
|
|
MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
|
-
(5)
- HY-P99384
-
|
B-701; MFGR-1877S; RG-7444
|
FGFR
|
Cancer
|
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P9803
-
|
SARS-80R; SARS antibody-80R
|
SARS-CoV
|
Infection
|
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
-
(5)
- HY-P991395
-
|
|
Tim3
|
Cancer
|
|
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
|
-
(5)
- HY-P9805
-
|
MERS-3A1; MERS antibody-3A1
|
SARS-CoV
|
Infection
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
-
(5)
- HY-P991346
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992484
-
|
|
Tau Protein
|
Neurological Disease
|
|
VY7523 is a monoclonal antibody and a selective inhibitor of pathological Tau. VY7523 reduces the propagation of pathogenic Tau in transgenic mouse models. VY7523 can be used in the research of Alzheimer's disease. The isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992330
-
|
KB312
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
CBT004 (KB312) is a human IgG1κ type monoclonal antibody against CD83. CD83 is a type I transmembrane glycoprotein and is a highly expressed marker on the surface of mature DCs. It can also be induced to be expressed on activated B cells, some activated T cells, and activated monocytes.
|
-
(5)
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
-
(5)
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
-
(5)
- HY-P990043
-
|
VGL101
|
Ser/Thr Kinase
TREM receptor
|
Inflammation/Immunology
|
|
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
|
-
(5)
- HY-108730A
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
|
-
(5)
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
(5)
- HY-P992404
-
|
|
TNF Receptor
|
Cancer
|
|
MDX-1401 is a fully human IgG1 (κ isotype) monoclonal antibody against CD30, with a Kd value of 0.83 nmol/L. MDX-1401 induces antibody-dependent cellular cytotoxicity in CD30-expressing cells and inhibits tumor growth in CD30 + lymphoma xenograft models. MDX-1401 can be used in research related to malignant lymphoma and Hodgkin lymphoma .
|
-
(5)
- HY-P990902A
-
|
BMS-986012 (FUT8-KO)
|
Inhibitory Antibodies
|
Cancer
|
|
Atigotatug (FUT8-KO) is an anti-fuc-GM1 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out, and fucose deficiency enhances the ADCC effect of the antibody. Atigotatug (HY-P990902) is a Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer .
|
-
(5)
- HY-P9991
-
|
TST001
|
Gap Junction Protein
|
Cancer
|
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
-
(5)
- HY-P991253
-
|
|
IGF-1R
|
Cancer
|
|
BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991487
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
LASN01 is a human IgG1 monoclonal antibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991443
-
|
|
CD73
|
Cancer
|
|
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991491
-
|
|
SARS-CoV
Influenza Virus
|
Infection
|
|
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
(5)
- HY-P991867
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991070
-
|
|
TNF Receptor
|
Cancer
|
|
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991067
-
|
KP-104
|
Complement System
|
Inflammation/Immunology
|
|
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
|
-
(5)
- HY-P990238
-
|
|
EGFR
|
Inflammation/Immunology
Cancer
|
|
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8 + T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer .
|
-
(5)
- HY-P990177
-
|
|
Notch
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse Notch4 Antibody (HMN4-14) is an anti-mouse Notch4 IgG monoclonal antibody. Anti-Mouse Notch4 Antibody (HMN4-14) reduces inflammation by restoring the expression of bispecific proteins. Anti-Mouse Notch4 Antibody (HMN4-14) can inhibit Th2/Th17 cell differentiation and improve Treg cell function. Anti-Mouse Notch4 Antibody (HMN4-14) can be used for research on inflammation conditions such as viral pneumonia and airway inflammation .
|
-
(5)
- HY-P990795
-
|
|
Osteopontin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonal antibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control (HY-P99981) .
|
-
(5)
- HY-P991447
-
|
|
VISTA
|
Cancer
|
|
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990247
-
|
|
E-Selectin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse E-selectin/CD62E Antibody (9A9) is an anti-mouse E-selectin/CD62E IgG2b monoclonal antibody. Anti-Mouse E-selectin/CD62E Antibody (9A9) has an inhibitory effect on cancer cell colonization. Anti-Mouse E-selectin/CD62E Antibody (9A9) can be used for researches on inflammation conditions and cancer such as acute microvascular inflammation and breast cancer .
|
-
(5)
- HY-P991961
-
|
|
CTLA-4
|
Cancer
|
|
REGN4659 is a fully human anti-CTLA-4 monoclonal antibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice .
|
-
(5)
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
-
(5)
- HY-P99123A
-
|
|
CD28
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).
|
-
(5)
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
(5)
- HY-P991708
-
|
REGN-4336
|
PSMA
CD3
|
Cancer
|
|
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
|
-
(5)
- HY-P992326
-
|
|
PDGFR
|
Inflammation/Immunology
Cancer
|
|
BOT1711 is a human IgG1κ monoclonal antibody targeting PDGFRB/CD140b. PDGFRB/CD140b belongs to type I receptor tyrosine kinases (RTKs), and is mainly expressed in vascular smooth muscle cells, pericytes, fibroblasts, certain mesenchymal stem cells, and tumor stromal cells.
|
-
(5)
- HY-P9970
-
|
Avakine; CT-P13; SB2; TA-650
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
The component ratio of this product is Active ingredient : Excipients = 9 : 47.
|
-
(5)
- HY-P990937
-
|
PF-04236921; TOUR-006
|
Interleukin Related
|
Inflammation/Immunology
|
|
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
|
-
(5)
- HY-P991406
-
|
|
TNF Receptor
|
Cancer
|
|
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
|
-
(5)
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
|
-
(5)
- HY-P99268
-
|
SAR 256212; MM 121
|
EGFR
Apoptosis
|
Cancer
|
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
-
(5)
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
-
(5)
- HY-P991066
-
|
ARGX-119
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
(5)
- HY-P992475
-
|
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P991636
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
|
-
(5)
- HY-P992354
-
|
INBRX-110
|
TNF Receptor
NF-κB
|
Cancer
|
|
FPA154 is a human monoclonal antibody against TNFRSF18/GITR/CD357. FPA154 activates NF-κB via the GITR pathway. FPA154 can be used in solid tumor research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991648
-
|
|
Interleukin Related
|
Cancer
|
|
CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research .
|
-
(5)
- HY-P99648A
-
|
BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
|
-
(5)
- HY-P99961
-
|
JS004; Icatolimab
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer .
|
-
(5)
- HY-P99837
-
|
SPV-T3a
|
CD3
|
Infection
|
|
Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
|
-
(5)
- HY-P992471
-
|
SYD1875 antibody
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
SYD1875 (SYD1875 Antibody) is an anti-5T4 antibody-drug conjugate (ADC) with anti-tumor potential. SYD1875 consists of a humanized IgG1 monoclonal antibody and a site-conjugated vc-seco-DUBA toxin. SYD1875 specifically binds to tumor cells that highly express carcinoembryonic antigen (CEA) 5T4, inducing apoptosis in these cells through DNA alkylation damage. SYD1875 can be used in research on aggressive tumors that highly express 5T4.
|
-
(5)
- HY-P990197
-
|
|
L-Selectin
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse MAdCAM-1 Antibody (MECA-367) is an anti-mouse MAdCAM-1 IgG2a monoclonal antibody. Anti-Mouse MAdCAM-1 Antibody (MECA-367) significantly inhibits the migration of pig peripheral blood lymphocytes (PBL) by blocking the function of MAdCAM-1. Anti-Mouse MAdCAM-1 Antibody (MECA-367) selectively inhibits B cell migration to exacerbate inflammation. Anti-Mouse MAdCAM-1 Antibody (MECA-367) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as colitis and diabetes .
|
-
(5)
- HY-P990206
-
|
|
Notch
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonal antibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE) .
|
-
(5)
- HY-P990246
-
|
|
Adhesion G Protein-coupled Receptors (AGPCRs)
|
Inflammation/Immunology
|
|
Anti-Mouse F4/80 Antibody (CI:A3-1) is an anti-mouse F4/80 IgG2b monoclonal antibody. Anti-Mouse F4/80 Antibody (CI:A3-1) can clear macrophages. Anti-Mouse F4/80 Antibody (CI:A3-1) can be used for research on inflammation conditions such as endometriosis. Anti-Mouse F4/80 Antibody (CI:A3-1) often used for flow cytometry analysis and immunohistochemical analysis .
|
-
(5)
- HY-P99132
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
|
-
(5)
- HY-P990121
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-4 Antibody (11B11) is an anti-mouse IL-4 IgG1 monoclonal antibody. Anti-Mouse IL-4 Antibody (11B11) can inhibit Th2 cell differentiation by blocking the IL-4 signaling pathway. Anti-Mouse IL-4 Antibody (11B11) can significantly reduce fibrosis combined with anti-IL13 mAb. Anti-Mouse IL-4 Antibody (11B11) can be used for researches on cancer and inflammation conditions such as colorectal cancer and prostatitis .
|
-
(5)
- HY-P990210
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse/Human IL-7 Antibody (M25) is an anti-mouse IL-7 IgG2b monoclonal antibody. Anti-Mouse/Human IL-7 Antibody (M25) alleviates inflammation by blocking IL-7 signaling and inhibiting innate lymphoid cells (ILC2s) activation. Anti-Mouse/Human IL-7 Antibody (M25) can reduce the number of B cell precursors. Anti-Mouse/Human IL-7 Antibody (M25) can be used for researches on inflammation conditions such as airway inflammation .
|
-
(5)
- HY-P990142
-
|
|
MHC
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse Vβ4 TCR Antibody (KT4) is an anti-mouse Vβ4 TCR IgG2b monoclonal antibody. Anti-Mouse Vβ4 TCR Antibody (KT4) can reduce the proportion of Vβ4 + T cells without affecting their function. Anti-Mouse Vβ4 TCR Antibody (KT4) can be used for research on immunology and infection conditions such as virus infection. Anti-Mouse Vβ4 TCR Antibody (KT4) is often used in flow cytometry .
|
-
(5)
- HY-P990204
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is a chimeric antibody of the original C9B7W antibody (HY-P99141). Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) contains the D265A mutation region. Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) can be used for research on cancer .
|
-
(5)
- HY-P991995
-
|
OMTX705 antibody
|
ADC Antibody
FAP
|
Cancer
|
|
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
|
-
(5)
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
Akt
p38 MAPK
Apoptosis
|
Cancer
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
|
-
(5)
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
-
(5)
- HY-P992344
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P990866
-
|
|
Interleukin Related
|
Cancer
|
|
Anti-CD25/IL-2Rα Antibody (7G7B6) is an anti-human CD25/IL-2Rα IgG2a monoclonal antibody. Anti-CD25/IL-2Rα Antibody (7G7B6) can inhibit the growth of tumors. Anti-CD25/IL-2Rα Antibody (7G7B6) can be used for research on leukemia. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
|
-
(5)
- HY-P99828
-
|
PF-06523435; hu24
|
ADC Antibody
RET
PERK
ROR
|
Cancer
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .
|
-
(5)
- HY-P99754
-
|
BCD-085
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99119
-
|
|
TNF Receptor
Bcl-2 Family
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
|
-
(5)
- HY-P99141
-
|
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
|
-
(5)
- HY-P991363
-
|
|
Myosin
STAT
|
Inflammation/Immunology
|
|
AX-202 is a humanized IgG4 monoclonal antibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .
|
-
(5)
- HY-P99239
-
|
HUJ-591; TLX591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
-
(5)
- HY-P99203
-
|
REGN-2810; SAR-439684
|
PD-1/PD-L1
|
Cancer
|
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
-
(5)
- HY-P9957
-
|
ABthrax
|
Bacterial
|
Infection
|
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
-
(5)
- HY-P9806
-
|
MERS-D12; MERS antibody-D12
|
SARS-CoV
|
Infection
|
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
-
(5)
- HY-P991178
-
|
|
TNF Receptor
|
Cancer
|
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
-
(5)
- HY-P991532
-
|
MEMD; EJ212/007-Cl2-5
|
ALCAM/CD166
|
Inflammation/Immunology
Cancer
|
|
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
|
-
(5)
- HY-P991569
-
|
|
Wnt
|
Metabolic Disease
Endocrinology
|
|
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
|
-
(5)
- HY-P991574
-
|
REG-101
|
ATGL
|
Cardiovascular Disease
|
|
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
|
-
(5)
- HY-P991947
-
|
AFS98; TG3003
|
c-Fms
|
Inflammation/Immunology
|
|
ELB041 (AFS98) is a rat monoclonal anti-murine c-fms antibody (IgG2a). AFS98 inhibits M-CSF–dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. AFS98 prevents development of fatty streaks in ApoE-deficient mice. ELB041 can be used for the research of atherosclerosis .
|
-
(5)
- HY-P990802
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
|
-
(5)
- HY-P990796
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
(5)
- HY-P990273
-
|
|
CD38
ERK
CD1
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
|
-
(5)
- HY-P990176
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is an anti-mouse OX40/CD134 (LALA-PG) IgG2a monoclonal antibody. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is a chimeric antibody of the original OX86 antibody (HY-P990115). Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can significantly enhance the generation of antigen-specific effector T cells. Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) can be used for research on cancer .
|
-
(5)
- HY-P990219
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-2 Antibody (JES6-1A12) is an anti-mouse IL-2 IgG1 monoclonal antibody. Anti-Mouse IL-2 Antibody (JES6-1A12) can inhibit Treg amplification and enhance Th1 response. Anti-Mouse IL-2 Antibody (JES6-1A12) can form a complex with IL-2 for experimentation. Anti-Mouse IL-2 Antibody (JES6-1A12) can be used for research on infection conditions such as malaria .
|
-
(5)
- HY-P990141
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse Vβ8 TCR Antibody (F23.1) is an anti-mouse Vβ8 TCR IgG2a monoclonal antibody. Anti-Mouse Vβ8 TCR Antibody (F23.1) can clear Vβ8 + T cells to alleviate immune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) can be used for research on autoimmune conditions. Anti-Mouse Vβ8 TCR Antibody (F23.1) is often used in flow cytometry .
|
-
(5)
- HY-P990201
-
|
|
L-Selectin
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is an anti-mouse L-Selectin/CD62L IgG2a monoclonal antibody. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can significantly inhibit the migration of T cells and B cells. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can block initial lymphocyte homing. Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) can be used for researches on inflammation, metabolic and infection conditions such as diabetes and parasitic infections .
|
-
(5)
- HY-P99138
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1a Antibody (ALF-161) is an anti-mouse IL-1a IgG1 monoclonal antibody. Anti-Mouse IL-1a Antibody (ALF-161) can inhibit CD8 + T cell response by blocking IL-1a signaling. Anti-Mouse IL-1a Antibody (ALF-161) can reversibly transform myeloid cell expansion and improve T cell function. Anti-Mouse IL-1a Antibody (ALF-161) can be used for researches on immune response and cancer such as breast cancer .
|
-
(5)
- HY-P990120
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonal antibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology .
|
-
(5)
- HY-P990250
-
|
|
Wnt
|
Inflammation/Immunology
|
|
Anti-Mouse DKK3 Antibody (DKK3-4.22) is an anti-mouse DKK3 IgG1 monoclonal antibody. Anti-Mouse DKK3 Antibody (DKK3-4.22) can improve kidney function and increases T cell infiltration. Anti-Mouse DKK3 Antibody (DKK3-4.22) can reduce skin inflammation by blocking the immunosuppressive function of DKK3. Anti-Mouse DKK3 Antibody (DKK3-4.22) can be used for researches on inflammation conditions such as unilateral ureteral obstruction (UUO) and experimental autoimmune encephalomyelitis (EAE) .
|
-
(5)
- HY-P99051
-
|
BAY 1834942
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
|
-
(5)
- HY-P99643
-
|
UCB6114
|
Dan family
|
Cancer
|
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
-
(5)
- HY-P99389
-
|
JNJ-64304500; IPH-2301; NN-8555
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D, with a KD value of 9.2 pM . Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease .
|
-
(5)
- HY-P991957
-
|
|
Prion Protein
|
Neurological Disease
|
|
PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.
|
-
(5)
- HY-P9970A
-
|
Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
|
-
(5)
- HY-P991247
-
|
|
MHC
|
Cancer
|
|
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
(5)
- HY-P99525
-
|
R 84 (antibody); GNR-011
|
VEGFR
|
Cancer
|
|
Varisacumab (R 84; GNR-011) is a fully humanized IgG1 monoclonal antibody targeting VEGF. Varisacumab specifically blocks the interaction between VEGF and VEGFR2, but does not interfere with the interaction between VEGF and VEGFR1. Varisacumab achieves effective anti-tumor and anti-angiogenic effects and can be used in the research of non-small cell lung cancer and pancreatic cancer.
|
-
(5)
- HY-P991557
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
ABI793 is a human IgG1 anti-human CD154 (CD40 ligand) monoclonal antibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection .
|
-
(5)
- HY-P99650
-
|
WT1
|
Transmembrane Glycoprotein
|
Cancer
|
|
Grisnilimab (WT1) is an IgG2a monoclonal antibody targeting CD7. Grisnilimab only binds to lymphoid tissues and T lymphocytes, with no off-target binding to normal tissues. Grisnilimab can be used to synthesize the immunotoxin WT1-SMPT-dgRTA, which exerts cytotoxic effects on T-lymphoblastic leukemia cells. Grisnilimab is applicable to relevant research on leukemia .
|
-
(5)
- HY-P991653
-
|
|
CCR
HIV
|
Infection
|
|
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
|
-
(5)
- HY-P990236
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonal antibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .
|
-
(5)
- HY-P990157
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is an anti-mouse Thy1/CD90 IgG2a monoclonal antibody. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can clear T cells from the spleen and bone marrow. Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) can be used for researches on immunology and inflammation conditions such as colitis .
|
-
(5)
- HY-P99126
-
|
|
Transmembrane Glycoprotein
CD44
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma .
|
-
(5)
- HY-P990249
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer .
|
-
(5)
- HY-P990680
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
|
-
(5)
- HY-P99045
-
|
HRS7; hRS7
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
(5)
- HY-P992176
-
|
|
CD47
|
Cancer
|
|
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10 -9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .
|
-
(5)
- HY-P990158
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Mouse Ter-119 Antibody (TER-119) is an anti-mouse Ter-119 IgG2b monoclonal antibody. Anti-Mouse Ter-119 Antibody (TER-119) can increase platelet count. Anti-Mouse Ter-119 Antibody (TER-119) can remove red blood cells and their precursor cells to isolate and enrich natural killer (NK) cells. Anti-Mouse Ter-119 Antibody (TER-119) can be used for research on immune thrombocytopenia. Anti-Mouse Ter-119 Antibody (TER-119) can be used to construct a model of immune thrombocytopenic purpura combined with CD41 mAb .
|
-
(5)
- HY-P990180
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonal antibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8 + T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma .
|
-
(5)
- HY-P990208
-
|
|
Interleukin Related
NF-κB
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-9 Antibody (9C1) is an anti-mouse IL-9 IgG2a monoclonal antibody. Anti-Mouse IL-9 Antibody (9C1) can reduce the activation of NF-κB signaling pathway and decrease the infiltration of inflammatory cells. Anti-Mouse IL-9 Antibody (9C1) effectively reduces Th9 cell-mediated allergic reactions and anti-tumor effects. Anti-Mouse IL-9 Antibody (9C1) can be used for researches on inflammation, infection conditions and cancer such as parasitic infections, allergic reactions, breast cancer and osteosarcoma .
|
-
(5)
- HY-P990196
-
|
|
P-glycoprotein
|
Cancer
|
|
Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is an anti-monkey/human MDR-1/CD243 IgG2a monoclonal antibody. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can efficiently inhibit P-glycoprotein. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) enhances the inhibitory effect on multidrug resistance (MDR) by suppressing drug efflux. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can be used for research on cancer .
|
-
(5)
- HY-P990165
-
|
|
RANKL/RANK
E1/E2/E3 Enzyme
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonal antibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis .
|
-
(5)
- HY-P990123
-
|
|
Transmembrane Glycoprotein
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis .
|
-
(5)
- HY-P99229
-
|
XMT-1535; Upinitatug
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991402
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
|
-
(5)
- HY-P9931
-
|
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
-
(5)
- HY-P991214
-
|
EMD 273066; huKS-IL2
|
Interleukin Related
|
Cancer
|
|
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .
|
-
(5)
- HY-P99190
-
|
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
-
(5)
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
|
-
(5)
- HY-P9907
-
Trastuzumab
Maximum Cited Publications
55 Publications Verification
Anti-Human HER2, Humanized antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
|
-
(5)
- HY-P99391
-
|
ABT-700; ABBV-400 antibody
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
(5)
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
(5)
- HY-P991651
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
|
-
(5)
- HY-P992450
-
|
|
TNF Receptor
|
Cancer
|
|
REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
|
-
(5)
- HY-P990198
-
|
|
Galectin
|
Inflammation/Immunology
|
|
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonal antibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry .
|
-
(5)
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99045A
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
(5)
- HY-P991229
-
|
AGS-1C4D4; AGS-PSCA
|
Complement System
|
Cancer
|
|
AGS-1C4D4 is a fully human IgG1κ monoclonal antibody targeting PSCA, with a Kd value of 0.2 nM. AGS-1C4D4 mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against PSCA-expressing cells. AGS-1C4D4 can be used for the research of pancreatic cancer .
|
-
(5)
- HY-P991892A
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
|
-
(5)
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
-
(5)
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P9971
-
|
SHR-1210; INCSHR1210
|
PD-1/PD-L1
|
Cancer
|
|
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
|
-
(5)
- HY-P991599
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990212
-
|
|
Interleukin Related
STAT
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonal antibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
|
-
(5)
- HY-P990248
-
|
|
Cadherin
EGFR
PERK
Akt
mTOR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonal antibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma .
|
-
(5)
- HY-P990134
-
|
|
TNF Receptor
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD40L/CD154 Antibody (MR-1) is an anti-mouse CD40L/CD154 IgG monoclonal antibody. Anti-Mouse CD40L/CD154 Antibody (MR-1) reduces the expression of IFN signaling pathway and lowers the level of IFN-β. Anti-Mouse CD40L/CD154 Antibody (MR-1) can prolong the survival time of transplants. Anti-Mouse CD40L/CD154 Antibody (MR-1) can be used for researches on cancer, inflammation conditions and xenotransplantation such as pancreatic cancer and autoimmune cholangitis .
|
-
(5)
- HY-P990214
-
|
|
Interleukin Related
Parasite
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-3 Antibody (MP2-8F8) is an anti-mouse IL-3 IgG1 monoclonal antibody. Anti-Mouse IL-3 Antibody (MP2-8F8) relieves joint inflammation by reducing synovial leukocyte infiltration and cytokine levels. Anti-Mouse IL-3 Antibody (MP2-8F8) can reduce the accumulation of basophils. Anti-Mouse IL-3 Antibody (MP2-8F8) can be used for researches on inflammation or infection conditions such as arthritis and parasitic infections .
|
-
(5)
- HY-P990001
-
|
|
Interleukin Related
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .
|
-
(5)
- HY-P990115
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 + T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .
|
-
(5)
- HY-P99055
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
-
(5)
- HY-P991620
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
|
-
(5)
- HY-P99248
-
|
Risankizumab rzaa; BI 655066; ABBV-066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
-
(5)
- HY-P991534
-
|
|
Amyloid-β
|
Neurological Disease
|
|
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
|
-
(5)
- HY-P991452
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonal antibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P990199
-
|
|
Inhibitory Antibodies
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) is an anti-mouse Ly6G/Ly6C IgG2b monoclonal antibody. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can deplete granulocytes and monocytes. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can be used for researches on infection conditions and cancer such as pancreatic cancer and Orientia tsutsugamushi infection .
|
-
(5)
- HY-P990151
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is an anti-mouse TL1A/TNFSF15 IgG monoclonal antibody. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can reduce TL1A levels and block TL1A-DR3 interactions. Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) can be used for research on inflammation conditions such as colitis and collagen-induced arthritis (CIA) .
|
-
(5)
- HY-P990160
-
|
|
MHC
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Anti-Rat TCR alpha/beta Antibody (R73) is an anti-mouse TCR alpha/beta IgG1 monoclonal antibody. Anti-Rat TCR alpha/beta Antibody (R73) suppresses immune response by depleting α/β + T cells. Anti-Rat TCR alpha/beta Antibody (R73) can inhibit the expression of pro-inflammatory cytokines. Anti-Rat TCR alpha/beta Antibody (R73) can extend graft survival time by reducing infiltration of T cells and neutrophils. Anti-Rat TCR alpha/beta Antibody (R73) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as arthritis, acute inflammatory peripheral neuropathy and diabetes .
|
-
(5)
- HY-145644
-
|
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
-
(5)
- HY-P99391A
-
|
ABT-700 (powder)
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
(5)
- HY-P990952
-
|
OMS906
|
Ser/Thr Protease
Complement System
|
Metabolic Disease
Inflammation/Immunology
|
|
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .
|
-
(5)
- HY-P990061
-
|
JTX 8064
|
LILRB
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
|
-
(5)
- HY-P991310
-
|
LT3015; LT-3000
|
LPL Receptor
|
Neurological Disease
Cancer
|
|
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992447
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .
|
-
(5)
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
-
(5)
- HY-P990193
-
|
|
MHC
|
Inflammation/Immunology
|
|
Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is an anti-mouse MHC Class I (H-2Kd, H-2Dd) IgG2a monoclonal antibody. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can block the interaction between Ly49 and MHC-I. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can be used for the construction of acute lung injury models .
|
-
(5)
- HY-P990161
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonal antibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer .
|
-
(5)
- HY-P99142
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) is an anti-mouse Ly-6G/Ly-6C IgG2b monoclonal antibody. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can deplete neutrophils and monocytes. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can be used for research on immunology .
|
-
(5)
- HY-P990781
-
-
(5)
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
-
(5)
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
(5)
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
-
(5)
- HY-P99340
-
|
VIR 7831; GSK-4182136
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
(5)
- HY-P991888
-
|
|
STAT
|
Cardiovascular Disease
Cancer
|
|
INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (KD = 1.75 nM for mutCALR del52; KD = 6.78 nM for mutCALR ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .
|
-
(5)
- HY-P992453
-
|
MTBT1466A; RG-6315
|
TGF-β Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
RO-7303509 (MTBT1466A; RG-6315) is a human monoclonal antibody and TGFβ3 neutralizer. RO-7303509 targets the profibrotic mediator TGFβ3 to alleviate fibrosis. RO-7303509 can be administered via subcutaneous or intravenous routes and is used in research on systemic sclerosis . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
-
(5)
- HY-P991654
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
|
-
(5)
- HY-P990801
-
|
|
Integrin
Parasite
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonal antibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
(5)
- HY-P990255
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 + cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer .
|
-
(5)
- HY-P990254
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
|
-
(5)
- HY-P990156
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) is an anti-mouse Thy1.1/CD90.1 IgG2a monoclonal antibody. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can deplete CD90.1 + cells. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can clear Tregs. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can be used for researches on inflammation conditions and immune response such as airway inflammation and experimental autoimmune encephalomyelitis (EAE) .
|
-
(5)
- HY-P990127
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse CD80/B7-1 IgG2a monoclonal antibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (TRM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant .
|
-
(5)
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
(5)
- HY-P990242
-
|
|
Galectin
TNF Receptor
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
|
-
(5)
- HY-P990132
-
|
|
CD47
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
|
-
(5)
- HY-P990237
-
|
|
CD28
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
|
-
(5)
- HY-P99121
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .
|
-
(5)
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990091
-
|
SAR 445088
|
Complement System
Fc Receptor (FcR)
|
Neurological Disease
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P9974
-
|
OMP-18R5
|
Wnt
|
Cancer
|
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
-
(5)
- HY-P991475
-
|
|
Transmembrane Glycoprotein
NF-κB
IFNAR
|
Cancer
|
|
MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991883
-
|
Licartin; Metuximab; Mehuzumab
|
Apoptosis
CDK
Caspase
Bcl-2 Family
|
Cancer
|
|
Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].
|
-
(5)
- HY-P991430
-
|
TB-403
|
VEGFR
|
Cancer
|
|
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
|
-
(5)
- HY-P991633
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
|
-
(5)
- HY-P991069
-
|
|
HIV
|
Infection
|
|
VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection .
|
-
(5)
- HY-P99867
-
|
MEDI 573
|
Inhibitory Antibodies
|
Cancer
|
|
Dusigitumab is a fully human IgG2λ monoclonal antibody that targets IGF-1 and IGF-2 with picomolar binding affinity. Dusigitumab blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R as well as activation of IR-A, thereby inhibiting the activation of downstream signaling pathways. Dusigitumab is applicable to research related to advanced solid tumors and hormone receptor-positive metastatic breast cancer .
|
-
(5)
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
-
(5)
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
IFNAR
|
Cancer
|
|
Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
|
-
(5)
- HY-P991220
-
|
|
TREM receptor
|
Neurological Disease
|
|
AL002 is a humanized monoclonal IgG1 antibody and a blood-brain barrier-permeable TREM2 modulator. AL002 binds to TREM2 on the surface of microglia, promotes TREM2 clustering and the formation of the TREM2-DAP12 complex, activates the TREM2 signaling pathway and PI3K cascade, and induces TREM2 internalization and degradation. AL002 is applicable to research related to Alzheimer's disease .
|
-
(5)
- HY-P991319
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
TAB-004 is a murine IgG1 monoclonal antibody that specifically binds to the tumor-associated hypoglycosylated mucin 1 (tMUC1), with high selectivity for human tMUC1. TAB-004 can be conjugated with Indocyanine green (ICG) (HY-D0711) for in vivo targeted imaging. TAB-004 can be used for the research of early detection, tumor progression monitoring and cancer stem cell targeting in breast cancer and pancreatic cancer.
|
-
(5)
- HY-P991609
-
|
|
MMP
|
Cancer
|
|
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
|
-
(5)
- HY-P991553
-
|
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
|
-
(5)
- HY-P991572
-
|
|
EGFR
|
Cancer
|
|
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
|
-
(5)
- HY-P99780
-
|
BIIB033
|
Transmembrane Glycoprotein
|
Neurological Disease
Inflammation/Immunology
|
|
Opicinumab (BIIB033) is a human IgG1 monoclonal antibody targeting LINGO-1. Opicinumab binds LINGO-1 to block its negative regulatory signaling, suppress axonal degeneration, enhance axonal regeneration, promote remyelination, and exert neuroprotective effects. Opicinumab maintains axonal protective effects during co-administration with methylprednisolone. Opicinumab can be used for the research of multiple sclerosis, acute optic neuritis, and optic neuritis. .
|
-
(5)
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
-
(5)
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P991585
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
|
-
(5)
- HY-P99242
-
|
|
CD276/B7-H3
|
Cancer
|
|
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
|
-
(5)
- HY-P991720
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
|
-
(5)
- HY-P991365
-
|
|
Transmembrane Glycoprotein
|
Endocrinology
|
|
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
|
-
(5)
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
-
(5)
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
(5)
- HY-P990131
-
|
|
CD47
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
|
-
(5)
- HY-P990004
-
|
|
Tim3
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8 + T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models .
|
-
(5)
- HY-P99125
-
|
|
Fc Receptor (FcR)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .
|
-
(5)
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Neurological Disease
|
|
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
|
-
(5)
- HY-P99146
-
|
|
CD3
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) is an anti-mouse TCR gamma/delta IgG monoclonal antibody. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can enter the blood-brain barrier. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) effectively depletes γδ T cells and reduces macrophage and neutrophil infiltration. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can reduce the immune response of transplants. Anti-Mouse TCR gamma/delta Antibody (UC7-13D5) can be used for researches on inflammation conditions, virus infection and cancer such as arthritis, JHM virus and breast cancer .
|
-
(5)
- HY-P992212
-
|
|
L-Selectin
|
Inflammation/Immunology
|
|
Anti-CD62L Antibody (DREG-200) is a human monoclonal antibody targeting CD62L/L-selectin. Anti-CD62L Antibody (DREG-200) binds to residues 45, 46 and 47 of L-selectin, and blocks L-selectin-mediated interactions, neutrophil rolling, adhesion, aggregation, secondary anchoring, as well as leukocyte rolling on ligands. Anti-CD62L Antibody (DREG-200) reduces myocardial necrosis, coronary endothelial dysfunction, and neutrophil migration driven by neutrophil microparticles. Anti-CD62L Antibody (DREG-200) exerts cardioprotective effects in feline models. Anti-CD62L Antibody (DREG-200) can be used in studies related to myocardial ischemia-reperfusion injury. The recommended isotype control is Mouse IgG1 kappa (HY-P99977) .
|
-
(5)
- HY-P991611
-
|
|
iGluR
|
Inflammation/Immunology
|
|
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
|
-
(5)
- HY-P991960
-
|
|
CTLA-4
Interleukin Related
|
Cancer
|
|
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
|
-
(5)
- HY-P991592
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .
|
-
(5)
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
(5)
- HY-P991864
-
|
MDX-124
|
Formyl Peptide Receptor (FPR)
|
Cancer
|
|
Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma .
|
-
(5)
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
(5)
- HY-P99613
-
|
MK-4280; Mavezelimab
|
LAG-3
|
Cancer
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P990661
-
|
|
c-Met/HGFR
ERK
PERK
|
Cancer
|
|
SAIT-301 is a Met-targeting monoclonal antibody. SAIT-301 inhibits Met activation, induces downregulated expression of phosphorylated Met(p-Met) and phosphorylated ERK(p-ERK), and reduces EGR-1 expression. SAIT-301 inhibits the migration and invasion of nasopharyngeal carcinoma cells. SAIT-301 is applicable to relevant research on nasopharyngeal carcinoma. For the isotype control of SAIT-301, refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992053
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-CD11a Antibody (MHM24) is a monoclonal antibody targeting murine CD11a. Anti-CD11a Antibody (MHM24) binds to high-affinity (open) and low-affinity (closed) conformations of the αL subunit of LFA-1, and functionally blocks LFA-1-mediated interactions. Anti-CD11a Antibody (MHM24) blocks ICAM-1 binding to LFA-1-expressing cells. Anti-CD11a Antibody (MHM24) inhibits adhesion of high-affinity LFA-1-expressing cells to keratinocytes. Anti-CD11a Antibody (MHM24) inhibits PHA-induced lymphocyte proliferation. Anti-CD11a Antibody (MHM24) can be used for the research of inflammatory and autoimmune diseases. Recommend Isotype Controls: mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
-
(5)
- HY-P991950
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P9980
-
|
GSK2857914
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
|
-
(5)
- HY-P990114
-
|
|
PD-1/PD-L1
|
Others
|
|
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .
|
-
(5)
- HY-P990294
-
|
|
Transmembrane Glycoprotein
STAT
Collagen
Reactive Oxygen Species (ROS)
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis .
|
-
(5)
- HY-P990253
-
|
|
Notch
EAAT
|
Inflammation/Immunology
|
|
Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) is an anti-mouse Delta-like protein 1/DLL1 IgG monoclonal antibody. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can reverse the inhibition of Treg cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can inhibit the upregulation of GLT-1 expression induced by endothelial cells. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) reduces autoimmune response by reducing B cell activation. Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) can be used for research on inflammation conditions such as lupus nephritis .
|
-
(5)
- HY-P990175
-
|
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonal antibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4 + T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC) .
|
-
(5)
- HY-P99959
-
|
MT-3921; rH116A3
|
TGF-β Receptor
|
Neurological Disease
|
|
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
|
-
(5)
- HY-P991567
-
|
VX5/5261
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
|
-
(5)
- HY-P99952
-
|
SCT400
|
CD20
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
|
-
(5)
- HY-145642
-
|
ZRC3308-A7
|
SARS-CoV
|
Infection
|
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
(5)
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
|
-
(5)
- HY-P991958
-
|
|
CTLA-4
|
Cancer
|
|
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
|
-
(5)
- HY-P99646
-
|
MEDI6570
|
LOX-1
|
Metabolic Disease
Inflammation/Immunology
|
|
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .
|
-
(5)
- HY-P991671
-
|
JNJ-80948543
|
CD3
CD20
Transmembrane Glycoprotein
|
Cancer
|
|
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
|
-
(5)
- HY-P991364
-
|
PYX-106; BSI-060T
|
Transmembrane Glycoprotein
|
Cancer
|
|
Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
|
-
(5)
- HY-145643
-
|
ZRC3308-B10
|
SARS-CoV
|
Infection
|
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
(5)
- HY-P992151
-
|
LT1002
|
LPL Receptor
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a Kd value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .
|
-
(5)
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
Bacterial
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
(5)
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
-
(5)
- HY-P991515
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
|
-
(5)
- HY-P9964
-
|
11F8; IMC-11F8; LY3012211
|
EGFR
|
Cancer
|
|
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
|
-
(5)
- HY-P990297
-
|
|
CCR
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
|
-
(5)
- HY-P990279
-
|
|
CD276/B7-H3
Apoptosis
STAT
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
|
-
(5)
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
-
(5)
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
-
(5)
- HY-P991551
-
|
|
Dipeptidyl Peptidase
p38 MAPK
ERK
|
Infection
Cancer
|
|
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
|
-
(5)
- HY-P99008
-
|
IC14
|
Toll-like Receptor (TLR)
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
|
-
(5)
- HY-P99176
-
ATG-031
4 Publications Verification
|
Inhibitory Antibodies
|
Cancer
|
|
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991424
-
|
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991598
-
|
MOR12743; MOR03207
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
|
-
(5)
- HY-P99027
-
|
LAG525; IMP701; Hu5A8
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
|
-
(5)
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
-
(5)
- HY-P990144
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
|
-
(5)
- HY-P992381
-
|
|
Drug Derivative
|
Cancer
|
|
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
|
-
(5)
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
(5)
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
(5)
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
(5)
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
-
(5)
- HY-P991656
-
|
|
CXCR
Apoptosis
p38 MAPK
Akt
|
Cancer
|
|
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
|
-
(5)
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
-
(5)
- HY-P991468
-
|
|
Interleukin Related
|
Cancer
|
|
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991855
-
|
|
TGF-β Receptor
|
Metabolic Disease
|
|
RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a KD of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation .
|
-
(5)
- HY-P991444
-
|
|
NTPDase
ATP Synthase
|
Inflammation/Immunology
Cancer
|
|
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .
|
-
(5)
- HY-P991584
-
|
|
FGFR
|
Cancer
|
|
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
|
-
(5)
- HY-P990690
-
|
MEDI-5752
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
|
-
(5)
- HY-P992413
-
|
|
Integrin
|
Inflammation/Immunology
|
|
MOR102 is a fully human IgG4 monoclonal antibody and an ICAM-1 inhibitor, lacking cross-reactivity with ICAM-2 and ICAM-3. MOR102 binds to the LFA-1 binding site within ICAM-1 domain 1, blocks ICAM-1/LFA-1 interaction, binds human keratinocytes with increased binding to interferon-γ-stimulated keratinocytes. MOR102 inhibits lymphocyte adhesion, reduces lymphocyte proliferation, prevents local T-cell activation, reduces inflammatory infiltrate, restores orthokeratotic differentiation, and reduces epidermal thickness. MOR102 can be used for the research of psoriasis .
|
-
(5)
- HY-P992335
-
|
|
Interleukin Related
|
Cancer
|
|
COM503 is a high-affinity anti-IL18BP human monoclonal antibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
-
(5)
- HY-P990252
-
|
|
Notch
Interleukin Related
NF-κB
VEGFR
FGFR
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .
|
-
(5)
- HY-P992437
-
|
|
CD44
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .
|
-
(5)
- HY-P991927
-
|
|
CD47
|
Cancer
|
|
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
|
-
(5)
- HY-P992382
-
|
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003 .
|
-
(5)
- HY-P99014
-
|
ARGX-110
|
Fc Receptor (FcR)
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
|
-
(5)
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
-
(5)
- HY-P99048A
-
|
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
(5)
- HY-P99390
-
|
MCLA 117
|
CD3
Interleukin Related
IFNAR
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
|
-
(5)
- HY-P990951
-
|
REGN-5381
|
Natriuretic Peptide Receptor (NPR)
|
Cardiovascular Disease
|
|
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .
|
-
(5)
- HY-P991000
-
|
AU-007; BD-8; BDG8
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99750
-
|
CT-P23
|
Influenza Virus
|
Infection
|
|
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
|
-
(5)
- HY-P991381
-
|
PPMX-T003
|
Transferrin Receptor
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cancer
|
|
JST‑TfR09 (PPMX‑T003) is a human monoclonal antibody (mAb) targeting transferrin receptor 1 (TfR1/CD71). JST‑TfR09 blocks the binding of transferrin to TfR1, inhibits TfR1 internalization, and suppresses cellular iron uptake. JST‑TfR09 triggers ferritin degradation via activating the autolysosomal system, promotes ROS production and lipid peroxidation, and ultimately induces ferroptosis. JST‑TfR09 exhibits cytotoxicity toward human erythroblasts differentiated from hematopoietic stem cells. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
-
(5)
- HY-P992390
-
|
|
CD3
|
Inflammation/Immunology
|
|
IOR-T3 is a monoclonal antibody targeting CD3, with biological activities related to T cell activation regulation . IOR-T3 uses its variable region to competitively engage surface CD3 on lymphocytes and trigger robust T cell proliferation and activation. IOR-T3 and its derivatives can be used in studies related to acute transplant rejection .
|
-
(5)
- HY-P991959
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
JMW-3B3 is a humanized IgG1λ monoclonal antibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.
|
-
(5)
- HY-P992410
-
|
|
PAI-1
TGF-beta/Smad
|
Inflammation/Immunology
|
|
MEDI-579 is a fully human monoclonal antibody against PAI-1, with a KD value of 6 pM for human PAI-1 and 105 pM for rat PAI-1. MEDI-579 restores renal plasmin activity and inhibits PAI-1-mediated intracellular signal transduction. MEDI-579 reduces albuminuria, glomerulosclerosis severity, TGF-β1 expression level, and phosphorylated Smad2 level induced in diabetic mice. MEDI-579 decreases the levels of active PAI-1 in plasma and kidneys, and increases plasma plasmin level in a mouse model of lupus nephritis. MEDI-579 can be used in research related to diabetic nephropathy and lupus nephritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P9996
-
|
LY3434172; IBI-318
|
PD-1/PD-L1
|
Cancer
|
|
Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer .
|
-
(5)
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
|
-
(5)
- HY-108831A
-
|
AN100226; BG00002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
|
-
(5)
Your information is safe with us. * Required Fields.
Inquiry Information
- 상품명:
- Cat. No.:
- 수량:
- MCE Japan Authorized Agent:
